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SUMMARY
Donor-specific blood transfusion (DSBT) prior to renal transplantation has been 
known to have a beneficial effect on graft survival for over twenty years. In 
experimental models the magnitude of this effect is markedly strain-dependent. Two 
principal MHC disparate rat strain combinations were used to examine possible 
mechanisms of DSBT induced tolerance of renal allografts in this study. The first of 
these was an established model where a single pretransplant blood transfusion 
produces tolerance (DA into PVG: fully MHC disparate). The second (R8 into RT1U: 
class I-disparate) involved the development of a new model where DSBT alone was 
ineffective but the addition of a short course of cyclosporin A (15mg/kg/day for 7 
days) at the time of the first of 4 weekly blood transfusions induced tolerance.
In the first model, DA into PVG, over 80% of animals showed long-term 
acceptance of a kidney allograft following a single 1ml DSBT 7 days prior to 
transplant. The tolerance was not tissue-specific and was independent of the thymus 
gland. Graft adaptation was seen in this model as passenger leukocyte depleted grafts 
survived for approximately 100 days in unmodified hosts (normal rejection time <10 
days). Cytokine levels present in rejecting, enhanced and syngeneic grafts were 
examined by semi-quantitative PCR. Levels of IFN-y, IL-4 and IL-10 were broadly 
similar in rejecting and enhanced grafts but the peak in IL-2 message around 4 days 
following transplant in the rejecting grafts was abrogated in the enhanced grafts.
In the second model, R8 into RT1U , tolerance was again achieved in >80% of 
animals and was independent of the thymus gland. No evidence was seen for graft 
adaptation. Graft acceptance following DSBT/cyclosporin A-pretreatment correlated 
with low levels of cytotoxic alloantibody while DSBT alone led to high alloantibody 
levels and graft rejection. Interestingly the production of intragraft Th2 cytokines 
correlated with graft rejection rather than tolerance. This observation may reflect the 
immunological role of alloantibody in causing graft damage in this experimental 
model whereas in other models alloantibody may tend to favour tolerance rather than 
rejection. This protocol for tolerance induction was also shown to be effective in a 
fully disparate strain combination (DA into Lewis) where it was found that increasing 
the number of transfusions improved graft survival.
Both of these models suggest that DSBT-pretreatments have a potential role 
in clinical practice especially when cyclosporin A is likely to be used as the principle 
immunosuppressant. DSBT is currently used in a small number of transplant centres 
but a greater understanding of the underlying mechanisms and development of a 
more effective protocol is required if its use is to become widespread.
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CHAPTER ONE 
Introduction
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1.1 A brief history of transplantation
The term transplant was initially used by John Hunter in 1778 when he 
described his work involving ovarian and testicular grafts between unrelated animals 
(Morris, 1982). However, the first successful series of grafts between unrelated 
humans was not achieved until as recently as the 1960’s.
The earliest recorded attempt at human organ transplantion was by a Russian 
surgeon, Voronoy, who in 1933 attempted unsuccessfully to treat, by renal 
transplantation, a patient suffering from renal failure secondary to mercury chloride 
poisoning. The transplanted kidney which was harvested six hours after the donors 
death, probably never functioned, and the unfortunate recipient died within 48 hours 
(Voronoy, 1936).
In the 1950’s a successful series of human renal transplants were carried out 
in Boston, USA (Murray et al., 1955). These were between identical twins, thus 
avoiding the immunological problems that had caused earlier transplants to fail 
acutely (Hume et al., 1955). This highly successful programme served notice of the 
potential of transplantation if the rejection response of the immune system could be 
suppressed. At this time there was no available medical treatment that could achieve 
this and transplantation was limited to this small group of patients with an identical 
twin willing to donate one of their kidneys.
Preliminary reports of a drug with potent immunosuppressive effects, 
6-mercaptopurine (Schwartz, 1959), were quickly followed by the demonstration of 
prolonged survival of renal allografts in dogs receiving the drug (Caine, 1960). The
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development of azathioprine, an equally effective but less toxic metabolite of 6- 
mercaptopurine (Caine et al., 1962), allowed successful human transplants to be 
performed and by 1963 the first patients to survive for a year following a cadaveric 
renal transplant were being reported (Murray et al., 1963). Corticosteroids were 
usually used together with azathioprine and the combination of these two agents was 
to become the standard therapy until the early 1980’s.
Also around the early 1970’s the somewhat surprising observation was made 
that transplant patients who had required blood transfusions, because of anaemia, 
prior to their renal transplant appeared to have a better outcome than those who had 
not (Opelz et al, 1973). Other transplantation centres confirmed this finding and the 
practice of random blood transfusion of potential cadaveric renal transplant recipients 
became established, although the number and frequency of transfusions varied from 
centre to centre. This use of blood transfusion as a beneficial treatment has to a large 
extent disappeared from current clinical practice due to the risk of sensitising the 
potential recipient and because the beneficial effect has become obscured by the use 
of better immunosuppressive drug therapy, notably cyclosporin A (Lundgren et al., 
1986).
Widespread introduction of the immunosuppressive agent cyclosporin A into 
clinical practice began in the early 1980’s. This compound is a metabolite derived 
from a soil dwelling fungus (Tolypocladium inflatum Gams) and is an extremely 
potent immunosuppressive agent (Borel et al., 1976). It was first shown by Caine 
and coworkers (1978) to be an effective immunosuppressive drug in renal
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transplantation and soon became used widely in this area. Employment of 
cyclosporin A, usually in combination with steroids and azathioprine, led to a one 
year graft survival figure, following cadaveric kidney transplantation, of between 80- 
85% (Green, 1988). Little improvement upon this figure has subsequently been 
achieved (UKTSSA, Bristol, 1994).
Over the last five years a number of novel immunosuppressive agents have 
been developed some of which, e.g. FK 506, are now being used in clinical practice. 
FK 506 appears to be especially useful in the field of liver transplantation (Murase et 
al, 1990). Other agents currently showing promise in animal models and competing 
for a potential role in the management of future patients include leflunomide 
(Williams et al, 1994), rapamycin (Chen et al, 1994) and brequinar sodium 
(Shirwann et al, 1994).
All the agents mentioned above have a major drawback as their basic action is 
to cause non-specific generalised depression of the immune system. This leads to a 
significant risk of morbidity and mortality from infection and, to a lesser extent, 
malignancy. In addition low grade rejection still is the main cause of graft failure in 
the long-term (Orosz et al, 1997). In the case of renal allografts approximately 3-5% 
of grafts functioning at one year following transplant will fail in each of the 
following years (Caine, 1987).
For these reasons a large volume of research, in the field of organ 
transplantation, is currently being directed at methods of manipulating the host 
immune system in a more selective manner with the aim of achieving specific
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immunological tolerance, thereby obviating the dangers inherent in blanket 
immunosuppression. This concept of prolonged graft function without long-term 
drug administration has been shown to be possible in a variety of animal models. 
Some of these animal models of tolerance and their possible application to the 
clinical situation are discussed later in this chapter.
From a clinical viewpoint the recent reports by Starzl and coworkers of 
survival of some longstanding human liver allografts, after discontinuing all 
immunosuppressive drug therapy, provides hope that immunological tolerance may 
be an achievable clinical goal (Ramos et al., 1995).
1.2 Immunogenetics of transplantation
1.2.1 The major histocompati bility complex (MHC)
At the start of the twentieth century it was demonstrated that acceptance or 
rejection of transplanted tumour tissue is under genetic control (Little and Tyzzer, 
1916). This idea was subsequently shown also to apply to normal tissues i.e. 
allografts (Medawar, 1944). The term histocompatibility loci was coined by Snell 
(1948) to describe the location of the genes governing transplant rejection with a 
major histocompatibility locus and other minor histocompatibility loci being 
identified.This division of loci was made on the speed of rejection of skin grafts;
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with major histocompatibility locus genes mediating a faster rejection response than 
minor histocompatt bility loci genes.
This major locus is now referred to as the major histocompati bility complex 
(MHC) and the others are collectively called minor histocompati bility antigens. The 
basic concept of a MHC has been identified in all vertebrate species studied although 
most work has been carried out on the human, mouse and to a lesser extent the rat. In 
the context of organ transplantation, the role of the MHC is essentially an unfortunate 
complication of the true biological function of a system that has evolved to allow the 
recognition of foreign antigens, e.g. microbial and viral proteins/peptides. The 
unrivaled degree of polymorphism exhibited by the MHC (Bodmer et al., 1994) 
provides a survival advantage for the species by maximising the probability that 
peptides originating from a pathogen can be presented by the MHC to allow the 
immune system to mount an effective response (Hill et al, 1991). Despite the 
complex nomenclature that has built up to describe the MHC of each species there is 
remarkable similarity in the basic structure and function of MHC between species. 
Figure 1.1 shows a diagrammatic representation of the MHC of mouse, rat and 
human.
The publication of high quality three-dimensional electron density maps 
(Bjorkman et al., 1987a) and the ability to identify and sequence the amino acids 
present has allowed the structure of the MHC molecule to be elucidated. This in 
combination with our rapidly increasing knowledge of the immune system, at the 
molecular level, has allowed an understanding of how the MHC system functions.
Mouse - H-2
K D
Rat - RT1
A
Human - HLA
D
—cz>
B D E
B C A
o >  Regions or loci encoding class I molecules 
Regions or loci encoding class II molecules
Figure 1.1 A simplified linear map showing the organisation of the 
major histocompatf bility complex (MHC)
The rem arkable sim ilarity o f the M HC in the m ouse, rat and hum an genom es is 
show n in diagram m atic form above.
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The class I MHC
Almost all nucleated cells in the body constitutively express polymorphic 
membrane glycoproteins known as class I MHC molecules on their surface although 
the level of expression can be up-regulated or down-regulated (Lew et al., 1986). 
These molecules consist of two non-covalently linked chains, a polymorphic heavy 
chain with a molecular weight of approximately 45 kilodaltons (kd) and a non­
variable lighter chain of 12 kd (P2 microglobulin).
The heavy chain is composed of three extracellular domains (a l, a2 and a3) 
linked by a transmembrane segment to an intracytoplasmic tail. The domains are 
arranged such that a l  and a2 form helical configurations on either side of a deep 
cleft, the floor of which is composed of 8 anti-parallel p pleated sheets. The cleft is 
occupied by a short peptide (most commonly a nonameric peptide) bound in an 
extended conformation (Madden et al., 1991). Such peptides have been sequenced 
and appear to match known self-peptides derived from intracellular proteins 
(Jardetzky et al, 1991). In the case of virally-infected cells, peptides derived from 
viral proteins have also been identified in the binding groove (Silver et al., 1992). 
Most of the polymorphisms in the class I MHC heavy chain are clustered around the 
cleft and therefore influence the nature of the peptide that can bind there (Bjorkman 
et al., 1987b). Peptides are provided via “the transporter associated with antigen 
processing” (TAP); a heterodimeric, MHC-encoded, ATP-dependent transporter 
molecule embedded in the endoplasmic reticulum membrane, with which newly
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synthesised class I MHC heavy chain P2-microglobulin complexes associate 
(Germain, 1995).
The class I MHC-peptide complex generally interacts with T lymphocytes 
only if they carry the CD8 costimulatory molecule (Monaco, 1992). This surface 
molecule is expressed on the T lymphocyte subpopulation responsible for cytotoxic 
killing of cells by way of direct contact and release of perforins and other toxins into 
the target cell (Berke, 1995).
Natural killer (NK) cells also exhibit specificity for MHC class I molecules in 
their interaction with target cells. These cells appear to be inhibited by the 
recognition of normal class I molecules and may play a role in regulating class I 
expression (Raulet, 1996). The role of these cells in relation to the rejection of organ 
allografts is poorly understood at the present time.
The class II MHC
In contrast to the widespread tissue distribution of class I MHC, class II 
molecules have a much more restricted distribution. Under normal circumstances 
these molecules are found predominantly on professional antigen presenting cells, 
notably B lymphocytes, macrophages, monocytes and dendritic cells. However, many 
other cell types can be induced to express class II MHC molecules given appropriate 
stimulation. Induction of class II molecules has been demonstrated in rejecting mouse 
skin grafts, on vascular endothelial cells and keratinocytes (De Waal et al., 1983;
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Dallman and Mason, 1983). Similarly donor tissue from directly vascularised rat 
heart and kidney allografts has been shown to express class II MHC molecules during 
rejection (Milton et al, 1986).
The three-dimensional structure of the class II MHC molecule has been 
published and several such molecules sequenced (Brown et al, 1993). They consist 
of two polypeptide chains of approximately 33 and 28 kd. Each chain is composed of 
an intracellular domain, a transmembrane domain and two extracellular domains. The 
extracellular domains, like the class I molecule, have a peptide binding groove, 
although, class II bound peptides are longer (~14 amino acids) and the peptide 
binding groove is open ended (Rudensky et al, 1991). Class II MHC molecules 
present soluble exogenous foreign peptide antigens following internalisation and 
processing by the antigen presenting cell to the T lymphocytes. Only T lymphocytes 
with the CD4 accessory molecule recognise the class II MHC-peptide complex 
(Monaco, 1993).
1.2.2 Minor histocompatibility antigens (mH)
When Snell coined the term major histocompatibility locus he also 
recognised the existence of other genetic loci (encoded outwith the MHC) that 
appeared to cause a weaker immunological response; these he named minor 
histocompati bility loci. Later studies have shown that these minor histocompati bility 
antigens are themselves capable of provoking powerful immune responses
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depending on the strain combination examined (Loveland and Simpson, 1986). In 
their study rapid rejection of skin grafts and cytotoxic T lymphocyte production was 
demonstrated in a mouse strain combination possessing identical MHC antigens. The 
minor histocompatibility antigens are widely scattered throughout the genome and 
are believed to be small endogenous peptides that occupy the antigen binding site of 
self-MHC molecules (Perreault et al, 1990). The exact numbers of these antigens is 
unclear but is potentially very high with over forty mH incompatibilities found 
between a single strain combination of mice (Bailey, 1975). The best characterised of 
these antigens the mouse H-Y antigen is a male specific transplantation antigen 
which has recently been identified and studied in detail (Scott et al, 1995).
1.2.3 High and low responder transplantation genes (Immune response genes)
Immune response genes were originally described prior to the identification 
of the MHC. The antibody response to a variety of synthetic polypeptides in the 
mouse was found to map to a region between H-2K and H-2D (McDevitt and Tyan, 
1968) and the genes encoded in this area were termed immune response genes 
(McDevitt and Benaceraff, 1969). Subsequently these genes were shown to be a part 
of the MHC.
In the field of transplantation, Howard and Butcher (1981) proposed the 
concept of immune response genes, linked to the MHC, that control the strength of 
alloimmune responses as measured by skin grafting, alloantibody production and in 
vivo cytotoxic cell production. Using a series of congenic rats with recombinants in
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their class I MHC (Butcher and Howard, 1977 and 1979) they later described the 
existence of a defect in antibody responses to transplantation antigens (Butcher et al., 
1982). On the basis of these immune responses they divided the recipient rats into 
“high” and “low” responder strain combinations. “High” responder genes led to high 
alloantibody levels and rapid graft rejection, while “low” responders did not reject 
their grafts and had undetectable alloantibody responses. Subsequently, using liver 
allografts, this division of immune responses was also seen to extend to a full MHC 
mismatch (Kamada et al, 1988) with “low” responders enjoying complete tolerance 
induction following liver grafting. Indeed, these liver grafted animals would 
subsequently accept heart allografts long-term.
A possible mechanism for this subdivision was proposed by Stewart and 
coworkers (1985a, and b) when it was reported that five-fold higher cell numbers 
were required to restore rejection to irradiated heart transplant recipients if the 
recipient was of a “low” rather than a “high” responder strain. Further experiments 
with this model, using chimeric cells for reconstitution, showed that the antigen 
presenting cells of the “low” responder host were defective at presenting an isolated 
class I MHC disparity. In contrast, if a full MHC haplotype mismatch was present 
then vigorous rejection occurred and was thought to result from the ability of donor 
class II molecules to directly induce host helper T cells thereby avoiding this 
defective presentation. Since the main source of class II MHC molecules in organ 
allografts are passenger leukocytes, which migrate out of the graft following 
transplantation, the importance of this direct presentation presumably decreases with
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time. This idea may explain why in “low” responder rodent models tolerance is often 
relatively easy to produce with short term courses of immunosuppressive therapies.
1.3 Mechanisms of allograft recognition and rejection
Classically the process of allograft recognition and rejection has been divided 
into three areas; an afferent phase where the graft releases foreign proteins into the 
host, a central phase where these proteins are processed and an efferent phase 
whereby the host immune cells primed by the foreign proteins attack their source.
As our knowledge of the complexity of the rejection process increases it has 
become obvious that this model is an oversimplification but it provides a useful 
framework for describing the stages of allograft rejection.
1.3.1 Afferent phase:-antigen release
For allograft rejection to occur the immune system of the recipient must 
recognise the presence of the graft. Early allograft experiments generally involved 
indirectly vascularised skin grafts and it was found that if the lymphatic drainage of 
these grafts was disrupted then rejection was dramatically delayed (Barker and 
Billingham, 1968). However, in directly vascularised organ grafts division of 
lymphatic drainage does not affect rejection (Pedersen and Morris, 1970). 
Splenectomy has been shown to prevent rejection of a renal allograft in a rat model 
(Fabre and Batchelor, 1975). These results led to the concept of graft antigens
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causing activation of the hosts immune system in a central compartment rather than 
host immune system cells becoming activated within the graft. Following skin 
grafting this activation occurred in the regional lymph nodes while in directly 
vascularised grafts the spleen was also important in terms of initiating rejection.
The identification of the dendritic cell population and their powerful 
immunostimulatory properties supported the concept of the graft shedding antigens 
into the host (Steinman and Witmer, 1978). These bone marrow derived cells have a 
striking morphology and have been shown to migrate from allografts into the lymph 
nodes and spleen of the recipient animal (Larsen et al, 1990). Elimination of these 
cells from the donor organ leads to a marked reduction of the rejection response in 
some animal models of allograft rejection. The most convincing demonstration of 
this effect involved retransplanting renal allografts, that have resided in a temporary 
host until these cells have left the graft (1 to 3 months), into a second unmodified 
syngeneic host. In some strain combinations such grafts show greatly prolonged 
survival but rejection was restored if donor-strain dendritic cells were administered at 
the same time as the retransplanted kidney (Lechler and Batchelor, 1982). Prolonged 
culture of pancreatic or thyroid tissues under conditions that are believed to destroy 
dendritic cells prior to transplantation also leads to prolonged survival of the grafted 
tissues (Lacey and Davie, 1984; Lafferty et al, 1975). These dendritic cells are 
generally referred to as passenger leukocytes, a term coined much earlier to describe 
the effect that immunisation with donor splenocytes or lymph node cells had on 
transplanted tumour tissues (Snell, 1957).
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Central sensitisation is not the only route for allograft recognition as 
elimination of passenger leukocytes does not always cause prolonged graft survival 
(Stuart et al, 1971). Peripheral sensitisation is also reported to occur as the host 
lymphocytes pass through the transplanted tissue (Tilney and Gowans, 1971).
Lanzavecchia has recently reviewed much of the current knowledge of the 
various mechanisms of antigen uptake for presentation to the immune system 
(Lanzavecchia, 1996). In the case of dendritic cells macropinocytosis and cell surface 
receptor mediated mechanisms principally the mannose receptor (mannosylated or 
fucosylated antigens) and FcyRII (antigen-antibody complexes) are important 
although alternative mechanisms may also exist.
1.3.2 Central phase:-antigen presentation
Conventional immune responses to exogenous protein antigens require that 
the antigen is taken up by a professional antigen presenting cell (APC) and processed 
before being presented to the T cell receptor (TCR) as a peptide in association with 
class II MHC molecules. These APC’s include dendritic cells, macrophages and B 
lymphocytes. In addition to presenting the processed antigen they also produce 
costimulatory signals that are required if the T cell is to produce its full range of 
functional and proliferative responses (Mueller et al., 1990; Muller and Jenkins,
1995). One of the principle costimulators is the B7 molecule which interacts with the 
CD28 receptor leading to activation and increasing adhesion of the T cell (Harding et 
al, 1992; Turcovskicorrales et al, 1995). Several other T cell receptors including
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CD27 and CD40 are also targets for costimulatory signals (Kobata et al., 1994; 
Vanessen et al., 1995). The particular APC involved may also affect the response 
seen, presumably as this will influence the costimulatory signals available. The role 
of secondary signals in the induction of T cells and graft rejection has recently been 
reviewed by Lafferty (1995).
Alloimmune responses are unique in that allogeneic class II MHC molecules 
are able to directly interact with and activate host T cells because they resemble self- 
MHC molecules carrying antigenic peptides in their binding grooves (Lechler et al., 
1990). This is referred to as the direct pathway of allorecognition. Dendritic cells 
express a very high density of class II molecules and are able to provide essential 
costimulatory signals. As such they are extremely potent at triggering immune 
responses and this is thought to be the major pathway involved in unmodified graft 
rejection (Braun et al., 1993).
Other potential sources of allogeneic class II MHC molecules are vascular 
endothelial cells. Rodent vascular endothelium does not however readily express 
class II MHC. This has led to problems in comparing results from these models with 
the human situation where class II expression on vascular endothelium is much 
greater. This may also explain why rodent models permit long-term graft survival to 
develop with relative ease.
There is now evidence that allogeneic MHC molecules may be processed in a 
similar manner to conventional exogenous protein antigens if shed from the graft into 
the recipients bloodstream. In this case it is the recipient APC’s that internalise donor
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antigen and present it as peptides in the binding cleft of self class II MHC molecules. 
This process is generally assumed to be less efficient but may become increasingly 
important depending on the particular circumstances involved. This is called the 
indirect pathway of allorecognition. Strong evidence for its existence has been shown 
by experiments, in both murine and rat models, where host T cells primed to 
alloantigens subsequently respond to peptides corresponding to the donor MHC; i.e. 
the MHC molecule has undergone processing by host derived APC’s (Benichou et 
al, 1992; Watschinger et al, 1994). A schematic model of allorecognition via the 
“direct” and “indirect” pathways is shown in Figure 1.2.
The final stage in allorecognition is when the specific MHC-peptide complex 
binds to the CD3/TCR complex in conjunction with the necessary accessory 
molecules. This leads to intracellular signalling and T cell activation. Much current 
research is being directed into this area. The first examples of the three-dimensional 
structure of TCR fragments have recently been published (Fields and Mariuzza,
1996). These confirm that the TCR is composed of a  and p (and also y and 5) chains 
with variable and constant domains analogous to those of antibodies. Further the V 
domains include hypervariable regions of polypeptide which are probably equivalent 
to the complementarity determining regions (CDR’s) of antibodies in that they 
mediate the peptide/MHC recognition. It is postulated that dimerisation of TCR’s is 
required for activation (Kolanus et al, 1993; Abastado et al, 1995) and also that this 
leads to conformational changes prior to signal transduction (Karjalainen, 1994; 
Janeway, 1995).
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1.3.3 Effector phase:-rejection mechanisms
The rejection of an allograft is characterised by a highly complex series of 
cellular and humoral interactions which combine to rapidly destroy an allograft in an 
unmodified host. There is now a consensus that the central and essential component 
of these responses is the T lymphocyte. The use of cloned cell lines and inbred 
animal models has allowed researchers to separate to some degree the different 
effector mechanisms which make up the immune response. The debate over the 
relative importance of delayed-type hypersensitivity reaction (DTH); cytotoxic T 
lymphocytes (CTL’s); helper T lymphocytes (T h); natural killer cells (NK) and 
alloantibody continues. The evidence for each of these potential mechanisms will 
now be discussed in turn.
Delayed-type hypersensitivity reaction
The historical similarities between the cells infiltrating rejecting skin grafts 
and those in DTH reactions led early workers to propose that DTH was responsible 
for allograft rejection (Brent et al., 1958). The basic principle of the DTH reaction is 
that Th cells following activation produce lymphokines eg. IL-2 and IFN-y that 
stimulate the recruitment and activation of non-specific effector cells such as 
macrophages which in conjunction with the proinflammatory cytokine TNF-a cause 
localised tissue destruction. Local synthesis of these three cytokines has been shown 
by detection of their mRNA in rejecting allograft tissues (Dallman et al, 1989).
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It is difficult to show that an allograft has been destroyed by DTH since there 
is no in vitro assay for detection. Consequently, destruction by DTH is generally 
implied rather than directly proven. Much of the evidence from rodent models 
suggests that non-specific DTH mechanisms do not have a major role in acute 
allograft rejection, if the help from the CD4+ T cell is excluded. DTH however may 
be more important in clinical organ graft rejection than in experimental models 
(Mason and Morris, 1986).
Cytotoxic T lymphocytes
The first direct evidence that CTL’s may play a major role in acute allograft 
rejection came in 1960 when it was demonstrated that thoracic duct lymphocytes, 
harvested from dogs that had rejected an allograft, were able to specifically lyse 
donor type renal epithelial cells in vitro (Govaerts, 1960). Subsequent experiments 
have shown that mature CTL’s cause cell killing by a direct action involving cell to 
cell contact without requirement for any lymphokines or help from macrophages or 
non-specific killer cells. The initial development of CTL’s however does require help 
in the form of IL-2 from Th cells.
The precise nature of this killing was established using skin grafts from 
allophenic mice. Such mice were created by fusing embryos of two allogeneic strains 
at the blastomere stage of development. When allophenic skin was grafted to either 
of the parental strains, those hair follicles bearing MHC molecules of the foreign 
parent were destroyed without any non-specific damage of hair follicles syngeneic
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with the recipient (Mintz and Silvers, 1970; Rosenberg et al., 1987). The ability of 
cloned CTL cell lines to cause tissue necrosis when injected intradermally into mice 
only if they express the minor H antigen to which the cloned cells are reactive is clear 
evidence that CTL’s can effect cell damage in vivo in such a precise manner (Tyler et 
al, 1984).
By extracting graft infiltrating cells from rejecting and non-rejecting grafts 
(treated with cyclosporin A) it has been demonstrated that only the rejecting grafts 
contained specific CTL activity although similar levels of non-specific activity were 
present in both groups (Bradley et al., 1985). This demonstration however, while 
being very suggestive of a role for the CTL, does not exclude other mechanisms and 
high levels of specific CTL activity can also be seen in some models where there is 
no apparent graft rejection (Armstrong et al, 1987).
Early experiments involving adoptive transfer of T cells into rats rendered 
immunodeficient by sublethal total body irradiation showed that the restoration of 
rejection of skin grafts with only mH differences was delayed if the restoring 
inoculum was depleted of cytotoxic cell precursors (Mason et al., 1984).
Other experiments using adoptive transfer of T lymphocytes into adult 
thymectomised, lethally irradiated and bone marrow reconstituted (ATXBM) mice 
and rats have shown that it is the CD4+ and not the CD8+ lymphocyte subpopulation 
which restores rejection (Loveland et al., 1981; Dallman et al., 1982). However 
CD4+ reconstituted rats still had a dense infiltrate of CD8+ T cells in rejecting grafts. 
Similar experiments in congenitally athymic rats restored with purified CD4+ T cells
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also found that CD4+ cells alone were required to cause rejection (Bolton et al, 
1989). This gave rise to the suggestion that the CD4+ Th cell is responsible for 
regulating graft rejection while the CD8+ lymphocyte may simply be one potential 
effector mechanism. Experiments by Hall and coworkers (1985) lent further weight 
to this hypothesis. They showed that CD4+ T cells alone could restore rejection of a 
cardiac allograft in acutely irradiated recipients. However transfer of both CD4+ and 
CD8+ cells together resulted in a faster rate of rejection.
Alloantibody
Antibody has long been accepted as the major cause of the severe endothelial 
damage that characterises the process of hyperacute rejection seen when a human 
kidney allograft is transplanted into a recipient with pre-existing cytotoxic 
alloantibodies (Kissmeyer-Nielsen, 1966). However the possible role of antibody in 
causing acute rejection in the non-sensitised recipient is less clearly defined. As 
recently as 1990 Colvin stated in a review of the literature that there was no obvious 
role for antibodies in primary graft rejection. Other workers however have reported a 
close correlation, in renal allograft recipients, between circulating anti-HLA-class I 
antibody and acute rejection episodes (Halloran et al., 1992).
Experimental models in the past may have underestimated the potential of 
antibody as a cause of graft damage, since many rodents have a relative deficiency in 
the ability to fix complement (French, 1972). Also in some rodent models, 
administration of immune serum leads to a dramatic prolongation of graft survival, a
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phenomenon known as passive enhancement (Fabre and Morris, 1974). These 
findings taken with the marked cellular infiltrate seen on histological examination of 
rejecting grafts and the ease with which such cells can be studied in vitro may have 
contributed to the potential role of alloantibody in graft rejection to be neglected.
Recent experiments have clearly demonstrated that, in a high responder class 
I-disparate rat strain combination, acute rejection is associated with the production of 
high levels of anti-class I antibodies (Gracie et al, 1990a; Morton et al, 1993). 
Furthermore in these experiments passive transfer of immune serum triggered acute 
allograft rejection in both congenitally athymic and anti-CD4 treated recipients. 
Rejection was dependent on the presence of CD4+ lymphocytes to provide help for 
the production of anti-class I cytotoxic alloantibody.
Alloantibody could in principle lead to graft destruction either by complement 
fixation or by antibody dependent cellular cytotoxicity (ADCC). In the latter the 
specificity of the effector response is provided by antibody but the actual damage is 
mediated by killer cells that are otherwise non-specific. The role of ADCC in graft 
rejection is somewhat unclear since ADCC activity following transplantation has 
been observed both in stable and rejecting grafts (Gailiunes et al, 1978).
1.3.4 The central role of the CD4+ T lymphocyte
It is now clear that a variety of different effector mechanisms are responsible 
for graft rejection and that the relative importance of these may vary depending on 
factors such as the nature of the MHC disparity, the type of graft and the state of
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sensitisation of the recipient (Swain and Cambier, 1996). The CD4+ T lymphocyte 
plays a central role in orchestrating the various effector mechanisms. It does so by 
releasing a range of cytokines which provide help for generation of specific CD8+ T 
cells, maturation of B cells (Steele et al., 1996) and a variety of non-specific effector 
mechanisms. Because the CD4+ T cell plays such a crucial role in the graft rejection 
response it has become an obvious target for monoclonal antibody therapy in an 
attempt to modify graft rejection (Shizuru et al., 1990; Wood et al., 1991).
1.4 Clinical experience of blood transfusion prior to transplantation
1.4.1 Random transfusion (unrelated)
The use of donor-specific transfusions 7 or more days prior to transplant in 
the clinical setting is clearly not possible, with the exception of living related kidney 
donors, due to the nature of organ donation and the limits on organ preservation. 
When it was reported in 1973, contrary to expectations, that cadaveric renal 
transplant recipients who had received “random” blood transfusions, on the basis of 
clinical need (usually anaemia), appeared to have fewer rejection episodes and longer 
graft survival, then interest in blood transfusion in the clinical setting became intense 
(Opelz et al., 1973). The initial report was rapidly confirmed by other groups and the 
practice of deliberate preoperative transfusion became established for patients on 
renal transplant waiting lists. However the timing and number of transfusions
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required for maximum benefit was not clear. In a large study (> 1300 cadaveric renal 
transplants) the number of grafts functioning at one year rose from 42% in recipients 
who had never been transfused to 71% in those who had received over 20 units of 
blood (Opelz and Terasaki, 1978). At the other extreme a single transfusion prior to 
transplant was reported to raise 1 year graft survival rates from 26% to 70% (Persijn 
et al, 1984). Most transplant groups adopted transfusion protocols between these 
extremes with between two and five transfusions being most commonly employed. It 
was suggested that maximum benefit from blood transfusion was seen in those 
patients transplanted within three months of the transfusions (Hourmant et al., 1979; 
Wemer-Favre et al., 1979).
This increased benefit from blood transfusion in terms of overall graft 
survival had however to be balanced against the dangers of sensitising the potential 
recipient against HLA antigens expressed by a potential future kidney allograft. 
Following the introduction of cyclosporin A as the main immunosuppressive agent 
and improved results from HLA matching (especially for HLA-DR antigens) the 
benefits of random transfusion in renal transplantation declined, as did its routine 
usage (Ting, 1988). Reports from the cyclosporin A era suggest that random 
transfusion prior to cadaveric renal transplantation has no measurable beneficial 
effect (Lundgren et al., 1986) and may indeed decrease one year graft survival 
(Ahmed and Terasaki, 1992). The clinical need for blood transfusions has also 
declined in patients on long-term haemodialysis as the anaemia seen in these patients 
can be treated with recombinant erythropoetin. It is worth pointing out that the
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kidney is currently the only organ where detailed HLA typing is practical and 
routinely carried out. In the case of other organs, limited supply, shorter preservation 
times and unstable potential recipients combine to make HLA matching impractical 
and blood transfusion may have some remaining role here.
Donor-specific transfusion is clinically possible in two settings; living related 
donors and cadaveric donor regimes where the transfusion is given at the time of the 
transplant or up to 24 hours before. Both regimes are being used clinically in a small 
number of centres and are discussed below.
1.4.2 Living related donor-specific blood transfusion
By preconditioning with three donor-specific blood transfusions prior to 
transplant, Salvatierra and colleagues (1980) were able to improve the outcome in 
HLA one- haplotype mismatches to that seen in HLA identical matches: around 90% 
one year graft survival. This transfusion regime however led to the exclusion of 
approximately one third of potential live transplants due to sensitisation and 
cytotoxic alloantibody formation. Interestingly, if the sensitised patients were given 
further blood transfusions, only a third appeared to show a further increase in 
cytotoxic alloantibody levels and a further third showed a marked decrease in 
alloantibody levels (Opelz et al, 1981a). The latter group had a favourable graft 
outcome following transplantation and it has been suggested that this is due to
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specific immunological unresponsiveness induced by the blood transfusions (Opelz 
etal., 1981b).
1.4.3 Perioperative donor-specific blood transfusion
It is clear from animal models and also some clinical reports that blood 
transfusion has the potential to improve graft outcome in many cases. However the 
dangers inherent in random transfusion, as practised in the 1970’s, from sensitisation 
and viral infections such as HIV, hepatitis and cytomegalovirus has made it 
unacceptable in current clinical practice. Recent reports have shown that in animal 
models donor-specific blood transfusion given in conjunction with 
immunosuppression either at the time of the transplant (with FK506: Fabrega et al., 
1993) or 24 hours before the transplant (with cyclosporin A: Brunson et al, 1991) 
may have beneficial effects while avoiding sensitisation. Sensitisation is much less 
likely due to the close timing of the transfusion and the transplant. Furthermore as the 
blood transfusion is donor-specific there is not an increased risk of viral infection. A 
clinical trial of preoperative DSBT plus cyclosporin A reported a reduction in both 
severe rejection episodes (defined as requiring OKT3 treatment) and in donor- 
specific reactivity at six months post transplant measured by mixed lymphocyte 
reaction against stored donor spleen cells (Alexander et al., 1992). This practice is 
still fairly new and as such is not widely used but is one reason for continuing
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research into donor antigen as a means of inducing long-term donor-specific 
tolerance.
Perioperatively administered DSBT has also recently been shown to produce 
tolerance in a rat heart model if the immunoglobulin CTLA4-Ig is given 48 hours 
post transplant (Lin et al, 1994). CTLA4-Ig is an antibody that appears to block 
activation of lymphocytes and is discussed later (Section 1.6.1).
1.5 Experimental models of tolerance induction using donor-specific blood
transfusion pretreatment protocols
1.5.1 Tolerance
Clinical organ transplantation between genetically disparate individuals 
currently necessitates non-specific suppression of the recipient’s immune system for as 
long as the graft is present. Even with the best current immunosuppresive therapy, graft 
rejection remains the major cause of graft loss and drug related morbidity and mortality 
cause considerable problems for the graft recipient. It would be far superior if a strategy 
could be developed which allowed an individuals immune system to accept an allograft 
as though it was “self’ tissue and permit a normal immune response to potential 
pathogens without any requirement for continuing drug therapy. Such a state constitutes 
transplant tolerance in its truest sense.
Such tolerance was first seen in 1953 when it was shown that the delivery of 
foreign antigens into the developing immune system of neonatal mice, via the placental 
circulation, induced specific tolerance in the adult mouse. Skin allografts survived in 
tolerant animals only if related genetically to the cells in the neonatal transfusion
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(Billingham et al., 1953). Attempts to produce a similar state of transplant tolerance in 
adult animals, with a mature immune system, have also met with a considerable degree 
of success although this success has not yet been translated into clinical practice.
The main problem, as will be seen later, is that the species and genetic strain as 
well as the experimental protocol is extremely critical and no therapy has yet proved 
successful in an outbred population.
1.5.2 Donor-specific blood transfusion
Over 25 years ago it was shown that, in some rat models, tolerance to a 
vascularised allograft followed if the animal was transfused with donor-strain blood 
prior to transplant (Marquet et al., 1971; Fabre and Morris 1972). This was known as 
donor-specific blood transfusion (DSBT) and was made possible by the development of 
inbred strains of rat with defined histocompatibility antigens. The ability of DSBT to 
prolong graft survival is however highly dependent on the rat strain combination and 
the type of graft, as well as the nature, dose and timing of the blood transfusion. In 
some rat strain combinations a single 1ml blood transfusion given 7 days prior to 
transplant prolongs kidney allograft survival indefinitely while in other strains little or 
no beneficial effect is seen (Stewart et al, 1985a). Interestingly renal allografts appear 
to survive longer after donor blood transfusion than heart allografts, while skin allograft 
survival is not altered to any significant degree (Morris, 1980).
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Many groups of workers have investigated which cellular components in the 
donor blood transfusion are required to produce transplant tolerance (see Table 1.1) and 
it is now apparent that rather than a specific cell type it is the donor major 
histocompatibility (MHC) antigens that are critical if tolerance is to be achieved. The 
demonstrations that tolerance can also be produced using cells from the spleen (Seki et 
al, 1989) or the liver (Foster et al, 1989) as a source of donor antigen and the elegant 
studies by Madsen (1988) using syngeneic fibroblasts transfected with donor class I and 
class II MHC alloantigens to produce prolongation of allograft survival reinforce this 
idea. Although intact donor cells are not required, the form the donor antigen is 
presented in is important; water soluble class I MHC does not readily produce tolerance 
while the same MHC molecules do when presented as insoluble protein micelles 
(Foster 1989).
DSBT can be viewed as a form of alloantigen pretreatment that stimulates the 
recipients immune system but renders it specifically unresponsive to the subsequent 
allograft. It is not a form of immunosuppression as DSBT-treated animals have a more 
rapid invasion of their grafts by leukocytes and a rapid induction of both class I and 
class II MHC relative to control animals (Armstrong et al, 1987). Indeed when these 
graft infiltrating cells from transfused recipients are tested in vitro for specific 
cytotoxicity it appears to be equal to or greater than that shown by cells extracted from 
rejecting grafts in non-transfused recipients (Dalman et al, 1987; Armstrong et al, 
1987).
Despite the accelerated cellular immune response to the graft following 
antigen pretreatment the grafts often enjoy prolonged function implying the existence
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Table 1.1
Ability of cellular components of allogeneic blood to enhance survival 
of organ allografts in the rat
Cell type MHC expression Enhancement
Class I Class II Yes No
B lymphocytes + + [1-5] -
T lymphocytes + - [4,5] [1,2,3]
CD4+T cells + - [4,5] -
CD8+ T cells + - - [4,5]
Erythrocytes + - [3,6,7] [1,2]
Platelets + - [8,9]
Renal allograft models: References [ 3,4,6,7,8,9 ] 
Cardiac allograft models: References [ 1,2,5 ]
References:
1 Lauchart et al., 1980
2 N agata^a/., 1984
3 El-Malik et al, 1984
4 Cranston et al, 1987
5 Oluwole et al., 1989
6 Majoor et al., 1981
7 Wood et al., 1985
8 Batchelor et al., 1977
9 Hibberd and Scott, 1983
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of a host regulatory mechanism(s) that can override the rejection mechanism(s) and 
allow the grafts to survive without any further treatment.
1.5.3 Immunosuppressive therapy combined with donor-specific blood
transfusion
Evidence that a short course of cyclosporin A (7 days 15mg/kg) at the start of 
a series of weekly blood transfusions abrogated alloantibody production suggested 
possible advantages in this combination of therapies (Jones et al, 1988; 
Cunnimfgham et al., 1988). These studies did not involve organ grafts but several 
other experimental models have been described using a variety of 
immunosuppressive strategies used in conjunction with DSBT including, cyclosporin 
A (Brunson et al., 1991), FK506 (Fabrega et al., 1991), anti-CD4 monoclonal 
antibody (Pearson et al., 1992) and CTLA4-Ig (Lin et al., 1993). The timing of the 
blood transfusion(s) and the immunosuppression relative to the transplant vary 
considerably but all these studies show that the combined strategy is more effective 
than either blood transfusion or immunosuppression used alone.
As newer, more potent immunosuppressive agents are introduced into clinical 
practice, the role of remote, random, or simple DSBT to enhance allograft survival 
will continue to diminish. However, as Fabrega and coworkers (1993) have pointed 
out these same agents may enhance the benefits of the administration of donor 
antigen in the form of DSBT’s. The view of Starzl and coworkers (1993) that 
immunosuppressive drugs may lead to tolerance by permitting donor-specific
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chimerism is a theoretical explanation for the synergistic use of immunosuppression 
and DSBT.
1.6 Potential mechanisms of unresponsiveness following donor-specific blood
transfusion pretreatment
1.6.1 T cell anergy
Jenkins and Schwartz (1987) demonstrated that if T cells were cultured with 
modified syngeneic APC’s (spleen cells that had been treated with a cross-linking 
chemical ECDI) the T cells were subsequently unable to proliferate in response to 
antigen presented by unmodified APC’s. The fact that these T cells proliferated 
normally when presented with a different antigen on the surface of unmodified 
APC’s showed that the cells were still potentially functional but they had become 
unresponsive to the original antigen. T cell anergy has been demonstrated in intact 
adult animals as well as in cloned cell lines (Dallman et al., 1991). This study 
showed that graft infiltrating cells from alloantigen tolerised animals had an inability 
to produce IL-2 or proliferate in response to exogenous IL-2 in vitro. However 
administration of exogenous IL-2 to these animals was able to reverse this anergic 
state.
The mechanism by which the T cell enters the anergic or unreactive state is 
not yet fully understood. Two signals are required to fully activate a T cell. The first 
signal is engagement of the TCR with the peptide antigen plus host MHC molecules 
(or allogeneic MHC alone) while the second signal is the interaction of one or more
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receptors on the T cell with appropriate ligands on the APC. Available evidence 
suggests that if the second signal is absent or insufficient then the signal arising from 
engagement of the TCR is a negative signal that effectively blocks further activation 
(Harding et al., 1992).
One candidate for the second signal is the CD28 molecule on the cell surface 
of the T cell. This binds to the ligand B7.1/7.2 on the cell surface of APC’s. 
Stimulation of CD28 by B7 when the T cell has been activated via its TCR leads to 
proliferation and lymphokine gene expression. There is also a further cell surface 
molecule CTLA-4 which is only seen following activation of the T cell via the TCR 
and this molecule also binds to B7.1/7.2 but with greater affinity than CD28. The 
physiological function of this molecule may be to prevent excessive immune 
responses to transient sources of stimulation (Schwartz, 1995). In terms of transplant 
rejection CTLA4-Ig is capable of blocking the interaction of CD28 with B7.1/7.2 due 
to its greater binding affinity and this has been shown to delay cardiac allograft 
rejection in the rat (Turka et al, 1992), presumably through lack of costimulation 
leading to a relative deficiency of IL-2 (Linsley et al, 1991).
1.6.2 Antibody
Antibody has long been suspected of having a role in the unresponsiveness 
seen following antigen pretreatment in some experimental models. An early finding 
was that administration of hyperimmune serum in many rodent models led, not to 
rapid graft destruction as expected, but instead to the development of specific
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unresponsiveness towards the allografts. This phenomenon appeared most 
pronounced if the alloantiserum was primarily directed against donor class II MHC 
molecules (Fabre and Morris, 1974). The finding that tolerance following DSBT is 
associated with high levels of anti-donor class II antibodies (Marshall et al., 1990) 
and the observation that serum from rat strains which spontaneously accept liver 
allografts (and will subsequently accept renal allografts of the same strain) contain 
anti-class II antibodies (Kamada et al, 1986; 1988) is strong evidence that anti-class 
II antibodies may be tolerogenic. Such alloantibodies have the ability to block donor 
Fc receptors and this may interfere with the host’s ability to mount a response against 
the graft or act by blocking direct allostimulation by sterically inhibiting antigen 
presentation (Marshall et al., 1990).
Failure of the host immune system to switch anti-class I from IgM to IgG 
following transplant is reported to correlate closely with strain dependent variation in 
the efficacy of DSBT (Wasowska et al., 1992). In this study rat renal allograft 
survival after DSBT was prolonged only if anti-class I IgG antibody levels remained 
low after transplantation. This finding fits well with reports that anti-class I antibody 
may have an important role in acute graft rejection (Oluwole et al., 1989b; Gracie et 
al., 1990).
Finally it is notable that the presence of anti-idiotypic antibodies following 
DSBT also correlates with tolerance induction (Ludwin et al., 1986). Although the 
significance of this finding is not clear these immunoregulatory antibodies may, in 
principle, contribute to the enhancing effect of blood transfusion on allograft survival
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either by directly blocking the TCR of antigen-reactive cells or by binding to the 
idiotype of alloreactive cells and facilitating their removal from the circulation by 
antigen-reactive cell opsonisation (ARCO) (Hutchinson, 1980; Bradley, 1991).
1.6.3 Clonal deletion
Clonal deletion of alloreactive T cells was an obvious early candidate 
mechanism to explain the induction of transplantation tolerance. This is undoubtedly 
the principle mechanism operating in the thymus to prevent the release into the 
periphery of large numbers of potentially auto-reactive T cells (Kappler et al., 1987). 
Clonal deletion appears to be a major mechanism underlying the induction of 
neonatal tolerance (MacDonald et al, 1988) but in several models where tolerance 
was previously believed to be due exclusively to clonal deletion it is now being 
suggested that clonal anergy may be partly responsible (Qin et al., 1989).
Clonal deletion/anergy in the periphery may be reinforced if the thymus is 
incorporated into the treatment protocol. In a study by Sharabi and Sachs (1989) 
transplantation tolerance was produced by whole body irradiation and monoclonal 
antibody (Mab) treatment. The combined use of anti-CD4 and anti-CD8 Mabs caused 
effective depletion of peripheral T cells from the blood and spleen. Interestingly, 
thymic T cells were not depleted, even though they were coated with Mab. Further 
thymic irradiation increased the degree of tolerance suggesting that residual T cells 
were important. In a mouse skin graft model of tolerance induced by intravenous
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alloantigen, surgical removal of the thymus 2-4 weeks prior to the experiment, was 
also shown to extend the period of tolerance produced (Kitagawa et al, 1990).
The role of the thymus in overcoming peripheral tolerance, in addition to its 
role in deleting auto-reactive T cells, has led to extensive investigation of protocols 
involving direct injection of donor antigens into the thymus combined with systemic 
immunosuppression (reviewed by Posselt et al, 1993). The concept behind these 
experiments is that if developing T cells in the thymus are exposed to graft antigens 
they may see these antigens as “self’ when they meet them subsequently in the 
periphery. This model proposes that direct involvement of the thymus leads to clonal 
deletion and is claimed to be analogous to tolerance induction to self antigens 
(Markmann et al, 1993).
1.6.4 Cytokines. The Thl versus Th2 hypothesis
As discussed earlier the CD4+ T cells can be divided into two functionally 
distinct sub-classes, Thl and Th2 cells, based on the spectrum of cytokines they 
produce (Mosmann and Coffman, 1989). More recent studies have extended this 
concept and postulated that both CD4+ and CD8 T+ cells can be divided into type 1 
and type 2 on this basis (Carter and Dutton, 1996).
Thl and Th2 cells are mutually antagonistic i.e. IL-2 and IFN-y promote Thl 
and inhibit Th2 whereas IL-4 promotes Th2 and inhibits Thl. It has been postulated 
that the relative balance between Thl and Th2 cells may be responsible for whether
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an allograft is accepted or rejected. In this hypothesis Thl cells are assumed to 
provide help for promoting graft rejection mechanisms while Th2 cells are believed 
to be involved in tolerance induction and maintenance (Lowry, 1993).
In so far as IL-2 is a Thl cytokine and reduction in IL-2 levels either 
pharmacologically, (e.g. cyclosporin A) or by intervention through DSBT, leads to 
prolongation of graft survival, then depressed Thl responses are associated with 
tolerance. The concept that raised Th2 cytokine levels are responsible for tolerance is 
more controversial. The persistent expression of IL-4 and IL-10 messenger RNA in 
the spleen and graft of mice (Takeuchi et al., 1992) and rats (Papp et al., 1992) 
bearing longstanding cardiac allografts has been taken as evidence that these 
cytokines are producing a tolerogenic effect within the microenvironment of the 
graft. It is important to note that cells other than T lymphocytes can also produce Th2 
cytokines, e.g. eosinophils are able to produce large amounts of IL-4.
Preferential activation of Th2 cells in rats treated with rapamycin has been 
reported to explain the prolonged survival of cardiac allografts with a selective 
inhibition of cytotoxic antibody production and normal non-cytotoxic antibody 
production (Ferraresso et al., 1994). Neonatal tolerance has also been recently 
reported to be associated with enhanced Th2 and diminished Thl cytokine levels 
(Chen and Field, 1995).
It is important to point out that while cytokine release following T cell 
activation may be vital to the outcome of an allograft following transplantation this 
does not exclude other mechanisms of graft acceptance. Thl but not Th2
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lymphocytes have been reported to be rendered anergic following in vitro antigen- 
receptor cross-linking if costimulatory signals are absent (Williams et al, 1990).
1.6.5 Suppressor cells including veto cells and infectious tolerance
Antigen pretreatment has been shown in a number of studies to lead to the 
development of a population of host cells with marked immunosuppressive 
properties. These cells appear able to prevent rejection of the graft. This is best 
demonstrated by the ability of T cells from tolerant animals to prevent allograft 
rejection when adoptively transferred to unmodified or “lightly irradiated” hosts. The 
first reports of such cells came from a mouse model involving lethal irradiation, 
syngeneic bone marrow rescue and a heart allograft (Jirsch et al., 1974). Several 
groups have also reported the presence of such cells following donor antigen 
pretreatments (Dorsch and Roser, 1977; Bril et al., 1985; Wood et al., 1985\ Hall, 
1985; Hutchinson, 1986). More recently, in a rat heart transplant model, peripheral 
tolerance seen following a short course of cyclosporin A has been claimed to be due 
to a transferable radiosensitive antigen-specific suppressor cell (Nisco et al., 1995).
A veto cell, is a cell which, if recognised by an alloreactive cell, kills the cell 
recognising it. The concept of veto cells was first proposed as a mechanism for the 
suppression of murine auto-reactive cytotoxic T cell precursors, (Muraoka and 
Miller, 1980) and subsequently postulated to play a role in transplant tolerance (Fink 
et al., 1988). Veto cells were later claimed to have a role in the prolongation of renal
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allograft survival in a primate model where the recipient animals were pretreated 
with anti-thymocyte globulin followed by transfusion with donor bone marrow cells 
after transplantation (Thomas and Carver, 1991). In these animals in vivo anti-donor 
CTL activity was abolished although production of anti-donor alloantibody was 
merely delayed, suggesting that a split state of tolerance had been produced. The 
authors postulated that the donor bone marrow contained a population of cells that 
were effectively able to prevent (or veto) activation of the host CTL’s. These donor 
cells may be able to interact with the host CTL’s directly rather than by inducing the 
production of more traditional host derived suppressor cells (Martin and Miller, 
1989).
The concept of infectious tolerance is an old idea and was first proposed by 
Medawar in the 1950’s (Billingham et al., 1953). They hypothesised that T cells, 
which are suppressed themselves, are able to confer their unresponsiveness to other 
naive immune cells. A recent report by Qin and coworkers (1993) showed that they 
were able to transfer tolerance by taking immune leukocytes from CD2+ transgenic 
mice (hCD2+/CBA), tolerant of mH antigens, and transferring them to a secondary 
host. This secondary host then became tolerant of the same mH antigens but only 
after they had been allowed to circulate in the second host for over 14 days. If they 
were eliminated before 14 days, in this case by administration of an anti-human CD2 
Mab, then tolerance transfer was abrogated.
Suppressor cells and veto cells may exert their immunological effects via the 
cytokine network discussed in the previous section. Many of the classical studies of
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these cells were carried out before the ability to measure and quantify cytokines 
became available.
1.7 Aims of this study
DSBT has been known to have beneficial effects on organ transplant survival 
in both clinical practice and in experimental models for over twenty years. However 
in current clinical practice blood transfusion is no longer used routinely, partly due to 
the significant numbers of patients who produce alloantibodies against future donor 
antigens rendering them unsuitable for transplantation (Burlingham et al, 1988) and 
also partly due to the improved results seen with modem drug-induced 
immunosuppression. There are many drawbacks to current immunosuppressive 
methods in terms of the non-specific nature of their actions and toxicity. The major 
cause of graft loss remains rejection and cancer rates are very significantly raised in 
patients following organ transplantation. Both of these factors demonstrate the 
continuing need for a method of producing genuine tolerance to a graft rather than 
merely suppressing rejection.
The mechanisms that operate to produce both the beneficial and the 
detrimental effects of blood transfusion remain elusive reflecting the current 
uncertainty about the genetic and immunological mechanisms involved, although our 
understanding of these is rapidly increasing. The rat model allows the immune 
responses to defined histocompati bility differences to be examined. In addition, the
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renal vessels in the rat are of a size that, with the aid of the dissecting microscope, 
renal transplantation can be carried out with a high degree of technical success. The 
work in this study has attempted to re-examine the “blood transfusion effect” and 
develop potential new strategies that could be used in current clinical transplantation. 
In addition this study has tried to use some of the recent developments in our ability 
to measure cytokine levels via the polymerase chain reaction to look at possible 
mechanisms behind the effect. Whilst care must be taken in extrapolating the 
findings in an animal model to the clinical situation any novel strategy for inducing 
tolerance will require such studies in the first instance before being applied to 
transplant recipients.
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CHAPTER TWO 
Materials and Methods
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2.1 Animals
Inbred male rats were used throughout this work. DA, Lewis, and PVG rats 
were purchased as required from Harlan Olac Ltd. (Bicester, Oxon, U.K.) and used at 
8  to 16 weeks of age (180 to 280g). PVG R8 and PVG RT1U rats were bred in the 
University of Glasgow animal facility from breeding pairs supplied by Harlan Olac. 
The MHC haplotype of the rat strains used is shown in Table 2.1.
Animals were housed in the animal facility of the University Department of 
Surgery, Western Infirmary, Glasgow. They were maintained under standard 
conditions with free access to fresh water and standard rat food.
2.2 Surgical procedures
2.2.1 Anaesthesia
All surgical procedures were performed under continuous inhalational 
anaesthesia using halothane and oxygen. Animals were not starved and no 
premedication was given prior to surgery.
Anaesthesia was induced by placing the animals in a perspex container filled 
with 4% halothane and oxygen. After shaving the operative site, anaesthesia was 
maintained by 2 % halothane and oxygen delivered by an anaesthetic nozzle placed over 
the animals nose and mouth.
During transplant operations the recipient animal was placed on a heater board
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Table 2.1 MHC haplotype of rats used in this study
Rat Strain A
RT 1 Region 
B D C
DA (RTla) a a a a
LEWIS (RT11) 1 1 1 1
PVG (RT1C) c c c c
PVG. R8 a u u u
PVG (RT1V) u u u u
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( 1 0  watt power) to maintain body temperature but this was switched off while the 
vascular anastomosises were fashioned to minimise potential warm ischaemic injury to 
the transplanted organ. Following completion of the operation the animals were placed 
in an incubator maintained at 37°C and observed until they were fully conscious. No 
post operative analgesia was required and the animals were able to return immediately 
to their preoperative diet.
2.2.2 Sutures
All sutures used during this work were purchased from Ethicon Ltd. 
(Edinburgh, U.K.). Types and sizes of sutures appear in the descriptions of the 
operations that they were used in.
2.2.3 Renal transplantation
All renal transplants were performed using the basic technique described by 
Fabre (1971) but with slight modification. The original bladder to bladder anastomosis 
was replaced by an end-to-end anastomosis of the donor and recipient ureters.
The donor rats abdomen was opened via a midline incision from xiphistemum 
to pubis and a self retaining retractor inserted. The intestines were wrapped loosely in a 
saline moistened swab and displaced to the right to expose the left kidney. If required 
the left lobe of the liver was also displaced from the operative field by a moist swab. 
The inferior vena cava was cleared of overlying fat by blunt dissection and the left
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ureter divided transversely approximately 1cm from the renal pelvis . The renal artery 
and vein were then mobilised and side branches ligated with 8/0 silk and divided. Any 
remaining perinephric fat was divided to leave the kidney suspended on its vascular 
pedicle. A moist swab was used to cover the opened abdomen of the donor animal and 
attention turned to the recipient animal.
The abdomen of the recipient was opened through a midline incision and the 
intestines and liver displaced from around the left kidney. The left ureter was then 
divided just below the renal pelvis and the renal artery and vein prepared as described 
for the donor animal. In approximately 50% of the PVG animals used as graft 
recipients a double renal artery was encountered. In these cases the lower artery was 
ligated and the upper renal artery used for the transplant anastomosis. Fortunately 
double renal arteries were rarely encountered in donor animals. Non-traumatic vascular 
clips (Scovill-Lewis) were then placed separately across the renal artery and renal vein 
close to the aorta and vena cava respectively. The renal artery and renal vein were then 
divided close to the hilum and the recipients left kidney excised.
The swab covering the donor kidney was then removed and, after confirming 
that the kidney was well perfused and had not been damaged by the earlier 
mobilisation, 1 0 0  units of heparin were injected directly into the inferior vena cava via 
a 25 gauge needle which was left in situ. Two minutes were allowed for the heparin to 
fully circulate before non-traumatic vascular clips were applied to the renal artery close 
to the aorta and, after the kidney had blanched, to the renal vein close to the vena cava. 
The donor renal artery and vein were then divided next to the vascular clamps and the
excised kidney placed in ice cold saline. Gentle external pressure was applied to flush 
excess blood out of the kidney.
The donor kidney was placed in the fossa produced by the removal of the 
recipient animals left kidney. Vascular anastomosises were then fashioned between the 
donor and recipients renal arteries and veins using interrupted 10/0 Ethilon sutures. 
Normally 6  sutures were used for the artery and 12-14 sutures for the vein. During these 
anastomosises ice-cold saline was infused intermittently into the abdominal cavity. This 
helped to reduce warm ischaemic damage and aided separation of the renal vein walls 
thereby allowing accurate placement of vascular sutures. Small pieces of Surgicell 
(Johnson & Johnson Ltd., Maidenhead, U.K.) were placed around the vascular 
anastomosises and the vascular clips removed, first from the renal vein and then from 
the renal artery. During this procedure gentle pressure was applied to the anastamosises 
using cotton buds (Johnson & Johnson Ltd.) to assist haemostasis. In the vast majority 
of cases (> 95%), the transplanted kidney displayed rapid and complete reperfusion and 
urine was seen to flow from the cut ureter. The heater board was then switched back 
on. The respective ends of the donor and recipients ureters were trimmed to the 
appropriate lengths and joined end to end. Satisfactory ureteric anastomosis was usually 
achieved with 4 interrupted 10/0 Ethilon sutures.
The abdomen was irrigated with warm saline, the bowels replaced, and the 
abdomen then closed using two layers of continuous 3/0 chromic catgut. The warm 
ischaemic period was consistently between 20-25 minutes and the overall incidence of 
vascular anastomotic failure was <5%.
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2.2.4 Contralateral nephrectomy
In survival experiments, unless otherwise stated, the native right kidney was 
removed on day 7 post transplant and survival of the animal after this time was 
dependent on adequate function of the transplanted kidney. Contralateral nephrectomy 
was normally carried out via a 2cm right subcostal incision. After delivering the kidney 
into the wound, the renal capsule was incised and reflected to expose the kidney 
extracapsularly. A clamp was then placed across the renal hilum, a single 2/0 silk 
ligature placed around the renal pedicle and the kidney excised. The nephrectomy 
wound was closed using two layers of continuous plain 3/0 catgut.
2.2.5 Cervical cardiac transplantation
Donor operation
The abdomen of the donor animal was opened and 100 units of heparin 
injected directly into the inferior vena cava. The heparin was allowed to circulate for 
one minute before the abdominal aorta and inferior vena cava were transected to 
exsanguinate the animal. The chest was then opened taking care to avoid damaging 
the heart. Cardiac arrest was achieved by placing crushed ice directly on the heart 
surface. The thymus was then excised to enable the great vessels to be visualised. 5/0 
silk ligatures were placed around the left and right superior vena cavae as well as the 
inferior vena cava and the veins transected on the proximal side of the tie. The donor
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aorta and pulmonary arteries were then transected immediately proximal to their first 
branches. Finally a 5/0 silk ligature was passed behind the heart and tied firmly to 
occlude any remaining vessels. All vessels entering or leaving the heart were thus 
ligated with the exception of the aorta and the pulmonary trunk. The heart was then 
excised from the chest and placed in a petri dish of ice cold saline.
Recipient operation
A 3cm longitudinal skin incision was made in the neck of the recipient animal 
to the right of the midline. The right external jugular vein was identified immediately 
before it passed underneath the clavicle and mobilised over approximately a 1cm 
length. Side branches were ligated with 8/0 silk and a non-traumatic vascular clamp 
applied immediately above the clavicle.The cranial end of the mobilised vein was 
then ligated with 5/0 silk and the vein divided just below the ligature. The 
stemomastoid and the strap muscles were retracted laterally and medially 
respectively and held with stay sutures to expose the right internal carotid artery. This 
was freed from its investing sheath and ligated with 5/0 silk immediately below its 
bifurcation. A non-traumatic vascular clamp was then placed across the artery low in 
the neck and the vessel divided obliquely (in order to increase the diameter for the 
anastomosis) immediately below the ligature.
The donor heart was placed in the neck such that the donor aorta and 
pulmonary artery were aligned with the recipient carotid artery and external jugular
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vein respectively and the vessels anastomosed in that order using interrupted 1 0 / 0  
Ethilon sutures. Surgicell was placed around the completed anastomosises, the 
vascular clamps removed and gentle pressure applied over the arterial anastomosis 
using cotton buds until any bleeding had stopped. The transplanted heart rapidly 
perfused and started to beat spontaneously, in sinus rhythm, after a brief initial period 
of fibrillation. The skin was closed over the heart using interrupted 3/0 plain catgut 
sutures.
Heart grafts were palpated daily and rejection taken as complete cessation of 
palpable impulses. Heart grafts which failed to beat during the first 24 hours after 
grafting (<5% of total grafts) were assumed to be technical failures and disregarded.
In later experiments a technical modification was made. Instead of the donor 
aorta being anastomosed directly to the recipients common carotid artery, the aorta 
was ligated just distal to its first branch and the smaller branch anastomosed to the 
recipient common carotid artery. Because the donor and recipient vessels were of 
similar size the vascular anastomosis was technically less demanding. This 
modification increased the operative survival rate but did not alter the fate of the 
grafts in any other way.
2.2.6 Skin grafting
The abdomen of the donor animal was shaved before the abdominal skin was 
excised in full thickness strips 1.5cm wide. All the subcutaneous fat was carefully
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removed and the strips trimmed to produce 1.5 cm x 1.5 cm grafts which were placed 
into chilled saline before application.
The recipient animal was shaved between its shoulder blades and a full 
thickness disc of skin 1.5cm in diameter was excised leaving the underlying fascial 
layer intact. The donor skin was then sutured into the resulting defect using 
interrupted 4/0 catgut sutures. The skin graft site was protected with occlusive 
bandages for 7 days and thereafter inspected daily for sign of graft rejection. 
Rejection was defined as >80% destruction of the graft.
2.2.7 Thymectomy
A 3 cm midline skin incision was made over the neck and upper part of the 
sternum. After identifying the stemomastoid muscles the manubrium was split in the 
midline. With the aid of an operating microscope, the pretracheal strap muscles were 
separated to reveal the upper aspect of the thymus gland. Exposure of the upper pole of 
the thymus was best achieved using an assistant to retract the overlying tissues. The 
upper pole was then mobilised and with steady retraction on the thymus gland 
combined with gentle separation of surrounding fat and blood vessels the entire gland 
was removed, usually intact. The manubrium was then reapproximated with a single 
5/0 silk suture and the skin closed with continuous 3/0 catgut. An overturned 2ml 
syringe was placed over the animals nose and mouth to allow the application of 
positive pressure air to the animals lungs and ensure full inflation. Mortality as a 
consequence of this procedure was <5%.
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2.3 Cells and tissues
2.3.1 Blood transfusion
Collection of large volumes of donor blood for transfusion was via direct 
cardiac puncture, of animals under terminal anaesthesia, with a 2 1  gauge needle on a 
10ml heparinised syringe. The blood was then transferred to a heparinised vacutainer. 
Transfusion was performed as soon as possible after collection using a 23 gauge needle 
via the dorsal penile vein of the recipient.
2.3.2 Blood sampling
Samples of up to 1ml were obtained by transecting the tip of the animals tail 
which was then cauterised with potassium permanganate after sufficient blood had 
been collected. These samples were allowed to clot prior to separation of the serum by 
centrifugation for 5min at 2500rpm and storage at -20°C for future analysis.
2.3.3 Lymph node cells
Cervical and mesenteric lymph nodes were removed from individual rats and 
pooled prior to use. The nodes were forced through a fine stainless steel mesh using a 
syringe plunger into 10ml of washing medium*. These cells were centrifuged at
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1300rpm for 5min and resuspended in 5ml of the same medium. This was carried out 
on two occasions to remove non-cellular contamination. The number of viable cells 
was counted using the tiypan blue exclusion test; cells were resuspended in 1ml of 
phosphate buffered saline (PBS) at the desired concentration before being transfused 
into the recipient animal.
*Washing medium comprised Hanks buffered salt solution (HBSS) + lOmM Hepes + 
2% heat inactivated foetal calf serum (FCS) (all from Life Technologies Ltd., Paisley, 
U.K).
2.3.4 Splenocytes
Spleens were placed in a petri dish with 10ml of washing medium (Section
2.3.3) and gently teased apart using sterile plastic forceps. The cell suspension thus 
produced was transferred to a plastic test tube and the debris allowed to settle out. The 
resulting cell suspension was spun at 1300rpm for lOmin (room temperature). The 
pellet was gently resuspended and the erythrocytes lysed by the addition of 5ml of 
distilled water followed closely by 5ml of double strength saline. The cells were spun at 
1300rpm and the pellet resuspended in washing medium on two further occasions to 
remove lysed cells and other debris. The viable cells were then resuspended in PBS, if 
they were to be returned to an animal, or in complete medium* if they were used for in 
vitro experiments.
* Complete medium comprised RPMI 1640 + lOmM Hepes + 10% foetal calf serum + 
2mM glutamine + penicillin/streptomycin (all from Life Technologies Ltd.).
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2.3.5 Concanavalin A stimulated lymphoblasts
Splenocytes from donor and third-party rat strains were stimulated with 
concanavalin A (Con A) to produce lymphoblasts for use as targets in chromium ( 51 Cr) 
release assays.
Splenocytes at a concentration of 2.0x106cells/ml in complete medium (Section
2.3.4) containing 2xlO'5M 2-mercaptoethanol were incubated with 5mg/ml of Con A 
(Sigma-Aldrich Company Ltd., Poole, Dorset, U.K.) in 25ml tissue culture flasks 
(Nundon, Life Technologies Ltd.) for 48-72 hours at 37°C in a humidified 5% CO2 
incubator. Lymphoblasts were washed once and counted prior to use.
2.4 Monoclonal antibodies
MRC 0X8 was used for the in vivo depletion of the CD8 + subset of T 
lymphocytes. This is an IgGl antibody specific for CD8 + T cells and also the majority 
of natural killer cells (Gillman et al., 1982; Dallman et al, 1982; Cantrell et al., 1982).
MRC 0X8 was produced in mouse ascites, following intraperitoneal injection 
of appropriate myeloma hybridoma cells (ECACC, Porton Down, Salisbury, Wiltshire 
U.K.) into pristane (Sigma-Aldrich Co. Ltd.) primed (DBA/2 x BALB/c)Fl mice 
(Harlan Olac Ltd.). The immunoglobulin content of the resultant ascitic fluid was 
quantified using anti-mouse IgGl immunodiffusion plates and known mouse Ig 
standards (Serotec Ltd., Oxford, U.K.). Antibody was diluted in PBS as required,
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aliquoted and stored at -20°C until used. It was administered to experimental animals 
by intraperitoneal injection immediately after thawing. Several mouse monoclonal 
antibodies (mAb) were used for in vitro experiments to label rat leukocytes as shown in 
Table 2.2.
2.5 Histology
2.5.1 Cryostat sections
Samples of freshly harvested renal allografts were embedded in OCT 
compound (Tissue-Tek, BDH Ltd., Poole, Dorset, U.K.), immediately snap frozen in 
liquid nitrogen and stored at -70°C. Cryostat sections (5pm) were then cut at -20°C 
onto gelatinised multispot slides (C.A. Hendley, Essex, U.K.).
2.5.2 Immunoperoxidase staining
Sections were fixed in acetone (BDH Ltd.) at room temperature for lOmin, and 
washed in PBS. Excess moisture was wiped carefully from each slide and 50pl of 
primary antibody, appropriately diluted, was applied to each section. Slides were then 
incubated for 45min at room temperature in a humidified chamber before being washed 
three times in PBS. A second antibody was then applied. This consisted of peroxidase-
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Table 2.2 Monoclonal antibodies used for in vitro experiments
mAb Specificity Reference
MRC 0X1 Leukocyte common antigen 
(LCA)
1
EDI Most tissue macrophages, 
monocytes and dendritic cells
2
R73 Constant determinant of the rat 
TCR-a/p
3
W3/25 CD4+ T lymphocytes and some 
macrophages
4
MRC 0X39 IL-2 receptor a  chain 5
MRC 0X21 Human C3b inactivator 6
All of the above rnAb’s were obtained from Serotec Ltd., Oxford, U.K.
References
1 Sunderland et al., (1979).
2 Dijkstra et al, (1985).
3 Hunig etal, (1989).
4 Mason et al, (1983).
5 Patterson et al., (1987).
6 Hsiung et al., (1982).
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conjugated rabbit anti-mouse Ig (Dako Ltd., High Wycombe, Bucks, U.K.) with the 
addition of 10% normal rat serum to absorb any cross-reactivity. After a further 30min 
incubation at room temperature the slides were washed three times in PBS and the 
substrate, 0.6mg/ml 3,3-diaminobenzidine tetrahydrochloride (Sigma-Aldrich Co. Ltd.) 
plus 0.01% hydrogen peroxide, applied for 5min. The sections were then lightly 
counterstained with Harris’s haematoxylin, dehydrated using increasing alcohol 
concentrations and cleared in xylene before finally being mounted in DPX (BDH Ltd.) 
for microscopic examination.
2.5.3 Morphometric analysis of cellular infiltrate
The area of each immunoperoxidase labelled tissue section infiltrated by 
leukocytes of a particular phenotype was determined by morphometric analysis using a 
point counting technique (McWhinnie et al., 1986). Sections were examined at a 
magnification of x400 in the presence of a microscopic eyepiece graticule bearing a 
squared grid with 745 intersections. For each of ten adjacent high power fields, the 
number of positively stained cells superimposed by an intersection was counted and the 
percentage area of each section occupied by cells of a particular phenotype was 
calculated as:
1 0 0  x number of positive cells under grid intersections 
total number of grid intersections
76
2.6 Functional assays
2.6.1 Complement dependent cytotoxicity assay
Serum samples were tested for the presence of cytotoxic alloantibody in a 
complement dependent cytotoxicity assay essentially as described previously 
(Winnearls et a l , 1979). Sera was heat inactivated at 56°C for 30min, centrifuged 
briefly to remove protein aggregates and then serially diluted in RPMI/5% FCS/lOmM 
Hepes. 50pl of each dilution was then mixed with 5xl04 51Cr-labelled Con A- 
transformed splenic blasts as targets (prepared from donor and third-party splenocytes 
as described previously in Section 2.3.5). Following incubation for 30min at room 
temperature, lOOpl of freshly reconstituted guinea pig complement (Sera-Lab., Sussex, 
U.K.) diluted 1:5, in RPMI/5% FCS/lOmM Hepes, was added and the cells incubated 
for a further lh at room temperature. Finally lOOpl of the supernatant was removed and 
counted in a gamma counter (LKB Wallac, Milton Keynes, U.K.). Target cells were 
also incubated with medium alone to determine spontaneous release and with 1 0 % 
Triton X-100 (Sigma-Aldrich Co. Ltd.) to determine maximum release. A serum 
sample with known high cytotoxic alloantibody level was also tested in each assay as a 
positive control. The % specific 51Cr release was calculated by the formula:
Experimental Release - Spontaneous Release x 100
Maximum Release - Spontaneous Release
Antibody titre was expressed as the lowest dilution that gave >20% specific killing.
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2.6.2 The mixed lymphocyte reaction (MLR)
LNC’s were used in allogeneic one-way mixed lymphocyte reactions (MLR’s) 
to assess the degree of long-term donor-specific tolerance following DSBT (donor- 
specific blood transfusion) and transplantation. LNC’s were used in preference to 
splenocytes since early experiments indicated the superior proliferative properties of 
these cells.
LNC’s were prepared and resuspended at a final concentration of 
8.0x106cells/ml in complete medium (Section 2.3.4) containing 2xlO'5M 2- 
mercaptoethanol and 5% normal rat serum. Irradiated (2000rads) donor-strain 
splenocytes (8 .0  x 1 0 6/ml in complete medium) were used as stimulator cells.
4.0x105 responder and stimulator cells were added to each well of a 96 well 
sterile round-bottomed microtitre plate (Nunclon, Life Technologies Ltd.), in triplicate,
A T
and incubated at 37 C in 5% CO2 for 3, 4 or 5 days. Each well was pulsed with H 
thymidine (1 pCi/well) for 16-18h prior to harvesting using a Dynatech Autowash 
Automatic Cell Harvester. Samples were then analysed in a liquid scintillation counter 
(LKB Wallac. Milton Keynes, U.K.).
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2.7 Analysis of cytokine mRNA
2.7.1 Total RNA extraction
All tissues destined for RNA extraction were excised, weighed and 
immediately snap frozen in liquid nitrogen prior to storage at -70°C.
TRIzol (Life Technologies Ltd.) was employed for RNA extraction. Tissues 
were homogenised directly in TRIzol (lml/lOOmg tissue) using a Polytron 
homogeniser. The homogenised samples were incubated (5min, room temperature) to 
permit complete dissociation of nucleoprotein complexes. Chloroform (0.2ml/lml 
TRIzol) was then added and the samples vortexed prior to incubation (3min, room 
temperature). Samples were then centrifuged (12000g, 15min, 4°C) and the upper 
aqueous phase removed to a fresh tube.
RNA was precipitated from the aqueous phase by mixing with isopropanol 
(0.5ml/lml TRIzol used for the initial homogenisation). Samples were incubated 
(lOmin, room temperature) and then centrifuged (12000g, lOmin, 4°C) producing a 
gel-like pellet of RNA on the side and bottom of the tube. The RNA pellet was 
washed in 75% ethanol (1ml) and spun (7500g, 5min, 4°C). Having decanted the 
supernatant the pellet was air-dried. Solubilisation of the RNA was achieved by 
resuspending the pellet in DEPC-H2O and incubating (lOmin, 55-60°C).
The approximate quantity and purity of total RNA were determined by OD260 
and OD26o/280 readings.
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2.7.2 First strand cDNA synthesis
First strand cDNA synthesis was performed using a Perkin Elmer DNA 
Thermal Cycler 480. 10pg of total RNA was primed with lpg (2pl) of oligo dT (Life 
Technologies Ltd.) for lOmin at 70°C. The mRNA was reverse transcribed in a 42pl 
reaction volume with 400u (2pl) of Superscript RNase H reverse transcriptase (Life 
Technologies Ltd.) for lh at 37°C. The enzyme was then heat-inactivated by 
incubation for 5min at 90°C.
2.7.3 The polymerase chain reaction (PCR)
For PCR, lpl of cDNA was amplified in a 25p,l reaction volume containing
0.1 p.1 Taq DNA polymerase, 0.4pl lOmM dNTP mix, 2.5pl lOx reaction buffer 
(lOmM Tris-HCl pH 8.3, 1.5mM MgCl2 , 50mM KCl)[all from Boehringer- 
Mannheim, Lewes, East Sussex, U.K.], 2.5pl each of sense and anti-sense primers 
(0.2pM final concentration [except (3-actin, 0.1 p,M]), and DEPC-H20 . A higher 
MgCl2 concentration (2.5mM) was used when amplifying IL-4 message. 
Oligonucleotide sequences for sense and anti-sense primers are detailed in Table 2.3.
PCR was performed using a Perkin Elmer Gene Amp PCR System 9600. An 
initial cycle at 94°C for 5min was followed by multiple cycles of 94°C for 30s, 45- 
65°C for 30s and 72°C for 30s and concluded with a final cycle at 72°C for 5min. 
During the exponential phase of amplification PCR product was sampled at three - or
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five - cycle intervals and analysed by electrophoresis on a 1.5% agarose gel and then 
stained with ethidium bromide. cDNA prepared from Con A-stimulated rat 
lymphoblasts served as positive control. Each PCR procedure also included negative 
controls in which cDNA and primer were omitted independently from the reaction 
mixture.
The identity of the PCR product was confirmed from the predicted size on gel 
electrophoresis and was further verified by Southern blot analysis using digoxygenin- 
ddUTP labeled (Boehringer-Mannheim) specific internal oligonucleotide probes 
selected from published gene sequences (Table 2.3).
The integrity of RNA preparation and reverse transcription was confirmed for 
each tissue by including a PCR for P-actin using three concentrations of cDNA (neat, 
1/10 and 1/100) each amplified for 15, 20 and 25 cycles. Tissue cDNA’s which did 
not generate the characteristic electrophoretic pattern for p-actin were prepared 
afresh prior to cytokine analysis. For all tissues each cytokine PCR was performed at 
least twice to confirm the electrophoretic pattern.
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Table 2.3 Oligonucleotide sequences for PCR primers
Cytokine Oligonucleotide sequences-sense primer (s) 
or anti-sense primer (a) and internal probe (p) 
receptor
Product 
size 
(base pairs)
Annealing Temp. 
(°C)
Ref*
IL-2
IL-2
IL-2
s 5' CATGTACAGCATGCAGCTCGCATCC 3 
a 5' CCACCACAGTTGCTGGCTCATCATC 3' 
p 5' TTACAGGTGCTCCTGAGAGG 3’
' 409 60 (1)
IL-4
IL-4
IL-4
s 5' TGATGGGTCTCAGCCCCCACCTTGC 3’ 
a 5' CTTTCAGTGTTGTGAGCGTGGACTC 3' 
p 5' GACTCCATGCACCGAGATGT 3'
377 60 (2)
IL-10
IL-10
IL-10
s 5' GTGAAGACTTTCTTTCAAA 3' 
a 5' TGATGAAGATGTCAAACTC 3' 
p 5' CTGAGGCGCTGTCATCGATT 3'
372 45 (3)
IFN-y
IFN-y
IFN-y
s 5' ATGAGTGCTACACGCCGCGTCTTGG 3 
a 5' GAGTTCATTGACAGCTTTGTGCTGG 3' 
p 5' AGCATGGATGCTATGGAAGG 3'
1 405 60 (4)
P-actin
P-actin
P-actin
s 5' ATGCCATCCTGCGTCTGGACCTGGC 3' 607 
a 5' AGCATTTGCGGTGCACGATGGAGGG 3' 
p 5' AGCAAGAGAGGTATCCT 3'
60 (5)
IL-2Rcc
IL-2Roc
IL-2Ra
s 5' GTGGGGAGATAAGGTGGACGCAT 3' 
a 5' GATCGAAAGGAGACAGGCACCC 3' 
p 5' TATCAGGTAGCAGTGGCCAG 3'
411 65 (6)
IL-2RP
IL-2RP
IL-2RP
s 5' TACTGGTCCTCGGCTGCTTCTTTG 3' 
a 5' GTGAAAGGCAGCAGAGGTGGGA 3' 
p 5'GACCATGCAGATGCTCCTGT 3'
493 65 (6)
* References
( 1 ) McKnight et al., (1989).
( 2 ) McKnight et al., (1991).
( 3 ) Feng et al., (1993).
( 4 ) Dijkema et al., (1985).
( 5 ) Nudel et al., (1983).
( 6 ) Page and Dallman (1991).
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CHAPTER THREE
Preliminary studies of donor-specific blood transfusion 
induced tolerance to renal allografts in a low responder 
rat strain combination
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3.1 Introduction to the DA into PVG strain combination
The ability of donor-specific blood transfusion (DSBT), in some experimental 
transplant rodent models, to lead to prolonged allograft survival has been recognised 
since the early 1970’s. This phenomenon is however markedly strain-dependent such 
that while no effect is seen in some strain combinations in others permanent graft 
acceptance follows (Fabre and Morris, 1972). In our early studies we sought to re­
establish a previously published rat model (Fabre and Morris, 1972) where DSBT is 
effective in producing long-term graft survival. This model was then used in studies 
designed to characterise the nature of this effect.
The initial rat strain combination used in this work was DA (donor) into PVG 
(recipient). This combination has been widely used in the past, both in our own 
laboratory and elsewhere, as a model where a single DSBT administered 7 days prior 
to transplant produces prolonged allograft survival. Several groups have reported 
indefinite survival of renal allografts (Fabre and Morris, 1972; Quigley et al., 1988) 
while for cardiac allografts survival is prolonged to ~20 days in most cases with a 
small number of grafts (20-30%) functioning for >100 days (Jenkins and Woodruff, 
1971).
The phenotype and function of the cells infiltrating renal allografts, either 
enhanced following DSBT or undergoing unmodified rejection, in this strain 
combination is already well characterised; however, the exact mechanism of 
enhancement remains unclear and requires further study. What is most striking from 
earlier studies is the apparent similarities in the cells infiltrating rejecting and non­
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rejecting grafts. Armstrong and coworkers (1987) showed that, in both cases, there 
was a heterogeneous mononuclear cell infiltrate that was composed of T cells, B 
cells, macrophages and natural killer cells. They also showed strong induction of 
both class I and class II MHC antigens in rejecting and non-rejecting grafts. The 
major difference found was the slightly accelerated time course of infiltration and 
MHC upregulation in the blood transfused animals (Milton et al, 1986). Similarly 
when graft infiltrating cells (GIC’s) were harvested from the transplanted organ in 
these animals and tested in vitro for both specific and non-specific cytotoxicity no 
differences were apparent. Wood and colleagues (1989) also found the cytotoxicity of 
GIC’s to be similar in both groups when tested in vitro. Adoptive transfer of GIC’s 
(harvested on day 5 post transplant) to fresh DSBT-treated animals (day 1 post 
transplant) indicated that GIC’s from tolerant grafts were functionally incapable of 
causing rejection whilst those from rejecting grafts were able to cause rejection 
despite DSBT-pretreatment of the second animal. These results suggest that in vitro 
tests may not reflect the complex interactions that can occur in vivo. For this reason 
much of the current study has examined the nature of the tolerance following DSBT 
using in vivo methods where possible.
In preliminary experiments we first sought to develop the microsurgical skills 
required for the renal transplant operation and used a conventional 
immunosuppressant drug, cyclosporin A, to prevent rejection. Once a high (>90%) 
rate of survival and graft acceptance was achieved we then attempted to confirm that
i.v. administration of donor blood, 7 days prior to transplant, also led to long-term
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graft survival and that this was a donor-specific effect as reported previously. 
Cyclosporin A was chosen, for these initial studies, as it is widely used in clinical 
practice and can be given in a convenient manner as a once-daily oral dose.
3.2 Results
3.2.1 Establishing the renal transplant operation using cyclosporin A
immunosuppression
In order to establish the renal transplant operation a group of ten PVG rats 
were transplanted with a DA kidney and treated with cyclosporin A at a dose of 
lOmg/kg/day for ten days. Dosing was by oral gavage and was started immediately 
on completion of the transplant.
Cyclosporin A-treated rats showed dramatically enhanced survival relative to 
control animals (Figure 3.1). When sacrificed at 100 days for histological 
examination of their renal allograft 9/10 animals remained in good health. The renal 
function of these rats (serum urea and creatinine) was also examined sequentially 
during this experiment. Most rats showed a small (<5%) and transient rise in urea 
and creatinine levels in the early days following the contralateral nephrectomy 
(Figures 3.2 & 3.3). Possible reasons for this brief rise include non-specific damage 
due to ischaemia at the time of transplantation, or transient self-limiting rejection, or 
even simply the effect of the animal becoming dependent on a single kidney. Renal
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Figure 3.1 Survival of PVG rats transplanted with DA kidneys and treated 
with cyclosporin A
Cyclosporin A, dissolved in olive oil, was administered (lOmg/kg/day) by oral 
gavage for ten days. The first dose was administered immediately on completion of 
the transplant. Control rats received olive oil only. Contralateral nephrectomy was 
carried out 7 days post transplant in all cases.
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Figure 3.2 Serum urea levels of cyclosporin A-treated PVG rats transplanted 
with DA kidneys
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Figure 3.3 Serum creatinine levels of cyclosporin A-treated PVG rats 
transplanted with DA kidneys
Cyclosporin A, dissolved in olive oil, was administered (lOmg/kg/day) by oral 
gavage for ten days. The first dose was administered immediately on completion of 
the transplant. Control rats received olive oil only. Contralateral nephrectomy was 
carried out 7 days post transplant in all cases. Serum urea (Fig 3.2) and serum 
creatinine (Fig 3.3) were measured on days 7, 9 and 11 post transplant. All values are 
plotted as mean +/- SD.
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function was then monitored until the end of the experiment (day 100). In 8/10 rats 
normal values were recorded at all points measured (serum urea <15mM: serum 
creatinine <120mM). One rat died of renal failure at day 36 and the other exhibited a 
small rise in urea (27mM) and creatinine (145mM) at day 100.
The prolonged survival seen after stopping treatment with cyclosporin A is 
interesting and has been documented previously in a variety of rat models (Morris, 
1981; Nisco et al., 1995). Histology of the surviving grafts at day 100 showed focal 
perivascular infiltration and cellular damage in keeping with low-grade rejection at a 
level that did not measurably alter renal function.
The prolonged survival achieved indicated that the renal transplant operation 
was sufficiently reproducible to allow investigation of any immunologically 
protective effect of DSBT.
3.2.2 Donor-specific blood transfusion and renal allograft rejection in the DA 
into PVG rat strain combination
Having demonstrated that the renal transplant operation was technically 
sound the next objective was to confirm that i.v. administration of 1ml of donor- 
strain whole blood 7 days prior to transplant led to long-term graft survival and that 
this effect was donor-specific.
Unmodified rejection, in this model, was shown to be rapid with no rats 
surviving longer than 10 days (Figure 3.1). In marked contrast DSBT-pretreated rats 
(lml DSBT day -7 relative to transplant) showed prolonged survival with overall
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long-term graft acceptance of almost 80% (Figure 3.4). This effect was clearly donor- 
specific as if a third-party blood transfusion (1ml Lewis whole blood day -7 relative 
to transplant) was given instead of donor-strain blood survival was identical to the 
unmodified rejection time. Graft rejection did not account for any death between days 
50 and 100 post transplant. After 100 days a gradual loss of grafts was observed 
although survival times of >300 days were seen. Of these longstanding grafts around 
30% were markedly hydronephrotic suggesting that some degree of ureteric 
obstruction or malfunction was present. The remainder were found consistently to be 
small in size with a white nodular appearance. These results would suggest that in 
DSBT-pretreated rats acute rejection has been replaced with a much more gradual 
process of chronic rejection.
Throughout the course of this work a small percentage of DSBT-pretreated 
animals died of histologically confirmed rejection at 12-14 days post transplant. For 
this reason the renal function of a number of allografts was followed closely in the 
first month following transplantation.
3.2.3 Early renal function following transplantation after DSBT
Survival alone is a rather crude method of assessing adequate renal function 
as any transient rejection episodes may not be noticed. The renal function of a group 
of 12 consecutively transplanted DSBT-pretreated rats was monitored by measuring 
the serum urea and creatinine over the first month post transplant. This was done to 
determine if all grafts underwent a degree of rejection that was spontaneously
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Figure 3.4 Preoperative blood transfusion and survival of DA 
kidneys in PVG rats
lml transfusions of either donor-specific blood (DSBT) or third-party Lewis blood 
(TPBT) were administered 7 days prior to transplant and a contralateral nephrectomy 
performed 7 days post transplant.
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resolved or if rejected grafts were responding in a different manner to the DSBT. 
Three patterns of renal function were seen. In half the rats (6/12) there was a limited 
rise in both urea and creatinine between days 12 and 18 post transplant to around 
double the expected levels. By the fourth week post transplant the renal function of 
these rats had returned to normal levels (serum urea <15mM; serum creatinine 
<120mM). In a small number of cases (2/12) the rise was much greater and one 
animal died of renal failure. The remaining rats (4/12) showed no rise in either urea 
or creatinine levels at any time measured post transplant.
3.2.4 The role of the thymus in DSBT-induced tolerance
Renal transplantation into thymectomised rats produced similar results to 
those obtained earlier in non-thymectomised rats. In the absence of DSBT, 
thymectomy did not appear to cause any reduction in the rate of rejection of renal 
allografts (Figure 3.5). This would indicate that the peripheral lymphocyte pool is 
sufficient to cause acute allograft rejection in these animals. Thymectomised DSBT- 
pretreated animal survival post transplant was also similar to that of animals with an 
intact thymus. The protective effect of DSBT does not appear to be diminished by 
prior thymectomy suggesting that this mechanism of tolerance production is 
peripheral in nature.
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Figure 3.5 Survival of adult thymectomised PVG rats transplanted with DA 
kidneys 7 days after donor-specific blood transfusion
All PVG rats thymectomies were carried out at least 4 weeks prior to the start of the 
experiment. Donor-specific blood transfusions (DSBT) of 1ml were administered 7 
days prior to transplant. Control thymectomised rats were transfused with 1ml of 
saline 7 days prior to transplant. Non-thymectomised DSBT-pretreated rats are also 
shown for reference. Contralateral nephrectomy was performed 7 days post transplant 
in all cases.
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3.3 Discussion of the preliminary studies in the DSBT renal 
transplant model
Over the course of this work we were able to re-establish a rat renal transplant 
model and confirm that preoperative blood transfusion can lead to long-term graft 
acceptance in a donor-specific fashion.
The close monitoring of renal function in transfused animals following 
transplantation suggests that many grafts undergo an initial period of mild rejection 
around two weeks following transplant. This manifests itself as a transient rise in 
serum urea/creatinine. In general a prolonged period of stable renal function ensues 
however, in some cases, rejection is severe and the animal fails to survive. When 
tolerance induction was achieved by conventional immunosuppression such as 
cyclosporin A rather than DSBT smaller fluctuations in serum urea/creatinine were 
observed. This suggests that these rises were not due to the transplant operation but 
reflected some active immunological process. The period of transient rejection noted 
shortly after grafting is similar to the observation of Stuart and coworkers (1968) 
who found that up to 50% of rats apparently tolerant of a renal allograft, using a 
protocol involving alloantigen and/or alloantibody, exhibited an increase in urea that 
was resolved by the second week post transplant.
Such grafts have been shown previously (Armstrong et al, 1987) to be 
heavily infiltrated by potentially damaging cells such as cytotoxic T cells and 
macrophages. This suggests that a balance exists between the rejection effector 
mechanisms of graft infiltrating cells and the tolerising effect of the DSBT.
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It is possible that if two separate DSBT’s had been used prior to transplant the 
number of tolerant animals obtained might have exceeded 80%. This was not tested 
during the current study, however another group (Bugeon et al, 1993) routinely 
administer two blood transfusions prior to transplant in a cardiac allograft model of 
the same strain combination.
The central role of the thymus in establishing an animals T cell repertoire 
during the development of the immune system has been accepted now for many 
years. It is generally assumed however that any continuing influence of the thymus 
over the peripheral T cell pool is of little importance beyond the neonatal stage. 
Previously it was thought that a blood-thymus barrier existed thereby effectively 
preventing thymocytes from seeing antigens expressed in the periphery (Burnet, 
1962); it was also presumed that mature T cells were excluded from the thymus 
(Gowans and Knight, 1964). A recent series of findings has suggested however that 
the adult rat thymus may not be as inactive as was first thought. Trafficking of 
thymocytes into cardiac allografts undergoing accelerated rejection and then back 
into the thymus has been described (Tanaka et al, 1992) and activated, rather than 
resting, T cells have been shown to be capable of penetrating the thymus (Agus et al., 
1991). Injection of donor blood directly into the thymus one day prior to transplant 
has resulted reportedly in tolerance to a renal allograft (Perico et al, 1992). 
Furthermore, the passive transfer of thymocytes from rats tolerised to vascularised 
organs into naive rats has been shown to prolong subsequent allograft survival in a 
strain-specific manner (Hendry et al, 1979).
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Thymectomy was carried out at least 4 weeks prior to either transfusion or 
transplantation. This time period was chosen to allow maturity of recent thymic 
emigrants (RTE’s) as it has been suggested that these cells may be more easily 
tolerised (Miller and Morahan, 1992). Reports in the literature suggest that RTE’s 
may account for -20% of circulating T cells in LNC’s of normal young adult rats 
(Hosseinzadeh and Goldschneider, 1993). Clearly this time delay is essential if the 
full effect of adult thymectomy is to be seen.
The efficacy of DSBT was identical whether or not the thymus was present 
with approximately 80% of thymectomised animals achieving long-term graft 
acceptance. Interestingly there was a group of animals that appeared to show reduced 
benefit from DSBT and rejected their graft around 12-14 days post transplant. Clearly 
this apparent failure of DSBT to achieve tolerance in these rats is not due to the 
emergence of a new population of cells from the thymus as has been reported in mice 
(Kitagawa et al., 1990).
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3.4 Summary
1 Unmodified rejection of DA renal allografts by PVG rats is 
rapid and survival is <10 days.
2 A 10 day course of cyclosporin A (lOmg/kg/day) following 
transplantation produces long-term renal allograft survival.
3 A single 1ml DSBT given 7 days prior to transplant produces 
long-term allograft survival in 80 % of animals.
4 Transplant tolerance induced by pretreatment with blood transfusion 
is donor-specific.
5 A transient self-limiting rejection episode is frequently observed 
during induction of tolerance by DSBT in this rat strain combination.
6 The thymus gland does not play an essential role in tolerance 
induction by DSBT.
97
CHAPTER FOUR
Investigation into the nature of tolerance produced by DSBT in the 
DA into PVG rat renal allograft model
98
4.1 Introduction
It has been found that the immunogenicity of an allograft decreases with time 
following transplant. This may contribute to prolonged renal allograft survival in a 
DSBT rat model (Marquet et al, 1985). In this study we have attempted to 
investigate the extent that the DSBT effect in the DA into PVG rat strain 
combination could be explained by such graft adaptation. We also tried to show that 
the immune system of the tolerant host was profoundly affected.
One possible mechanism of prolonged graft survival is that the graft itself 
undergoes a process of adaptation and modification following transplantation. This 
process effectively means that the host animal no longer recognises the graft as 
foreign tissue and the rejection response therefore declines as time passes despite the 
absence of any immunosuppression. One method of looking for graft adaptation is to 
retransplant the apparently tolerant graft into a fresh host without any form of 
immunomodulating therapy. This approach was first used by Batchelor and 
coworkers (1979) who were able to demonstrate prolonged survival of FI (AS x 
AUG) kidneys retransplanted from tolerised primary (AS) hosts to untreated 
secondary (AS) hosts. They were subsequently able to restore rejection of these 
tolerised grafts if small numbers of donor-strain dendritic cells were administered 
concurrently with the retransplantation of the graft (Lechler and Batchelor, 1982). 
These findings have been corroborated by other workers (McKenzie et al., 1984). It 
is now generally accepted that dendritic cells (passenger leukocytes), present within 
the allograft, form one of the main antigenic targets for rejection. An alternative test
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for graft adaptation is to consider whether introducing fresh cells into a tolerised host 
can cause destruction of a stable graft. The disadvantage of this approach is that these 
cells may be modulated by the host immune system before they are able to exert an 
effect on the allograft.
The effect of DSBT on the immune system of the host rat can be investigated 
using in vitro methods such as the mixed lymphocyte reaction and also by a variety 
of in vivo experiments using long-term surviving allograft-bearing rats. Both 
approaches were used in this study. The mixed lymphocyte reaction (MLR), in which 
T cells are stimulated to proliferate in response to allogeneic cells, provides an in 
vitro model of cellular alloreactivity (Hayry and Defendi, 1970). Previous studies in 
the rat have shown that proliferation of lymphoid cells, in response to donor antigen, 
is decreased in rats pretreated with DSBT compared to lymphoid cells from naive 
rats (Quigley et al., 1988). The reason for this effect is not entirely clear although 
there are probably both cellular and humoral factors involved.
4.2 Results: Graft related factors following transplantation
4.2.1 Passenger leukocyte depletion and graft survival
DA kidneys that had resided in a DSBT-pretreated PVG rat for at least 50 
days (these grafts are sometimes referred to as being “parked” in their initial 
recipient) were retransplanted into a second PVG rat. The second host received no
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treatment other than a contralateral nephrectomy 7 days post transplant. In all cases 
there was no evidence of acute rejection with grafts surviving at least 50 days in the 
second host. A severely attenuated rejection appeared to be occurring, in the longer 
timescale, with a mean survival time of 122 days (Table 4.1 and Figure 4.1). This late 
rejection of the grafts should also be considered in conjunction with the gradual loss 
in graft survival anticipated, with the course of time, had the grafts remained in their 
primary host. The fact that these grafts have now undergone a second transplant 
operation with a consequent further ischaemic period is also worthy of note.
4.2.2 The effect on graft function of transfusing sensitised lymphocytes into 
PVG rats bearing longstanding DA renal allografts following DSBT
Our earlier retransplantation experiments would suggest that the longstanding 
DA renal allograft in the PVG rat, following tolerance induction by DSBT, is a poor 
target for rejection due to the depletion of its passenger leukocytes. Consequently 
lymphocytes from PVG donors sensitised to DA antigens were transferred into PVG 
rats bearing DA renal allografts. Sensitised lymphocytes were produced by serial 
grafting of PVG rats with two DA skin grafts two weeks apart. Two weeks after the 
second skin graft lymph node cells (LNC’s) were harvested from cervical and 
mesenteric lymph nodes of the PVG rat and counted for viability. These LNC’s were 
transfused, in 1ml of PBS, into the PVG rat bearing the DA renal allograft via the
o
dorsal penile vein. A total of 10 unseparated viable LNC’s were given to each
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Table 4.1 Survival of retransplanted kidneys DA into PVG
Residence in first host Survival of second host Total survival of graft
(days) (days) (days)
229 91 320
50 138 188
50 145 195
100 >200 >300
50 67 117
50 62 112
100 86 186
109 >200 >300
161 108 269
Mean survival time 122 days
Primary PVG recipients (n=9) of DA renal allografts were pretreated with a 1ml 
DSBT 7 days prior to transplant. Following survival of the grafted animals for at 
least 50 days post transplant the grafts were excised and retransplanted into second 
untreated PVG hosts. All host rats underwent contralateral nephrectomy 7 days post 
transplant.
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Figure 4.1 Survival of naive PVG rats transplanted with either unmodified 
or previously “parked” DA kidneys
A renal allograft modified by initial transplant into a PVG rat tolerised to DA 
antigens by a 1ml DSBT 7 days prior to transplant was retransplanted, after at least 
50 days being “parked” in the first host, into a second PVG rat. The second recipient 
received no treatment either before or after receiving the retransplanted kidney. 
Contralateral nephrectomy was performed on all recipient rats 7 days post transplant.
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of three PVG rats bearing a DA kidney grafted, following DSBT, >50 days earlier. 
All three rats survived for >100 days following this adoptive transfer of cells primed 
against their grafts. The serum urea and creatinine of the rats were measured at 
intervals following LNC transfer and failed to show any rise that would suggest graft 
damage (Figures 4.2 & 4.3). Grafts which are well established appear extremely 
resistant to damage by infusions of fresh lymphocytes even if the lymphocytes have 
been sensitised previously against the MHC antigens of the allograft. It is not clear 
however if host mechanisms are acting to disable these cells or if the graft is simply a 
poor target.
4.3 Results: Host related factors following transplantation
4.3.1 The mixed lymphocyte reaction in PVG rats bearing long-term DA renal
allografts
Quigley and coworkers (1989a) have shown that at 4 days post DSBT, cells 
isolated from either thoracic duct lymph or the spleen of the transfused rat were 
capable of reducing proliferative responses in MLR reactions of naive cells in a 
strain-specific manner. They were also able to demonstrate that CD4+ T cells were 
responsible for this effect. It was of interest therefore to see whether depression of the 
MLR response was sustained in the long-term by using LNC’s from DSBT-pretreated 
PVG rats bearing DA renal allografts grafted at least 50 days earlier. Pooled cervical
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Figure 4.2 The effect on renal function (urea) of transfusing sensitised
LNC’s into PVG rats bearing longstanding DA renal allografts
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Figure 4.3 The effect on renal function (creatinine) of transfusing sensitised 
LNC’s into PVG rats bearing longstanding DA renal allografts
DA kidneys were transplanted into PVG recipient rats (n=3) 7 days post DSBT
o
(lml). >50 days later sensitised LNC’s (10 ) were transfused into the graft-bearing 
rats. Following LNC transfer, blood samples were taken at intervals from the 
recipient rats and analysed for serum urea (Fig. 4.2) and creatinine (Fig. 4.3).
105
and mesenteric LNC’s (2xl05) from either these “tolerised” rats or naive PVG rats 
were mixed with irradiated DA splenocytes (2xl05) and proliferation measured by 
the incorporation of H thymidine on days 3, 4 and 5 of the MLR (Figure 4.4). 
Similar results were obtained using LNC’s from 3 other “tolerised” PVG rats.
Whilst there is still some proliferative response to donor-specific antigen, the 
proliferation of the “tolerised” LNC’s was markedly reduced in comparison to that of 
naive LNC’s. This finding is similar to the fall in the MLR response of LNC’s taken 
from rats 7 days post DSBT treatment as reported previously (Quigley et al., 1988). 
Our result would suggest that donor-specific response to antigen remains depressed 
in the long-term following transplantation.
4.3.2 Retransplantation of fresh renal allografts into tolerised rats
Before DSBT-pretreated PVG rats can be said to be tolerant of DA kidney 
antigens it must be shown that long-term survival is not simply due to the 
transplanted kidney having undergone a process of graft adaptation such that it no 
longer presents a target for the host’s immune system: an effect which has already 
been shown to play a significant role in this strain combination (Section 4.2). On this 
occasion, the original DA renal allograft of a PVG rat “tolerised” by DSBT (1ml, day 
-7 relative to transplant) was excised 3-4 months after the original transplant and 
replaced immediately with a second DA kidney. No additional therapy was given to 
the PVG recipient after the original DSBT-pretreatment. On all four occasions in
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Figure 4.4 MLR comparing the proliferation of LNC’s from “tolerised” and 
naive PVG rats
Unseparated LNC’s (2xl05) pooled from cervical and mesenteric nodes of either 
“tolerised” or naive rats were used as responder cells in the MLR. “Tolerised” PVG 
rats had been transplanted with a DA kidney 50 days earlier following DSBT- 
pretreatment; naive PVG rats had no previous exposure to DA antigens. Irradiated 
DA spleen cells (2xl05) were used as stimulator cells. The proliferative response was 
assessed by measuring the incorporation of H thymidine on days 3, 4 & 5 of the 
MLR.
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which this procedure was carried out the new renal allograft also enjoyed long-term 
acceptance and in addition the renal function remained normal. There was no 
transient rise in serum urea (Figure 4.5) or serum creatinine (Figure 4.6) often seen 
following the original transplant (as described in Chapter 3; Section 3.2.3). This 
suggests that the long-term surviving PVG rats had achieved a state of tolerance 
towards DA strain kidneys. The second graft would have contained a normal 
complement of dendritic cells (passenger leukocytes) and would be expected to show 
the same transient rise in urea and creatinine as the first graft unless there had been 
some alteration of the host’s immune system as a consequence of the first renal 
transplant.
It was also important to demonstrate that tolerance remained strain-specific 
and was not explained by some non-specific depression of the immune system such 
as exhaustion of the effector mechanisms of rejection caused by persistent antigen 
load. In order to achieve this, the original tolerant kidney was again excised after 3-4 
months but this time it was replaced with a third-party kidney (Lewis strain). This 
procedure was again carried out on four occasions however, two very different 
outcomes were observed. As expected, two rats showed a period of normal renal 
function followed by a lethal rise in urea as the new graft was rejected (Figure 4.7). 
Interestingly the survival time of these rats was 17 and 18 days compared with a 
mean of 9 days (n=4 actual survival 9,9,9,9 days) for naive PVG rats transplanted 
with Lewis kidneys. This result suggests that some degree of protection also extends
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Figure 4.5 Renal function (urea) of a second DA kidney transplanted into a 
“tolerised” PVG rat
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Figure 4.6 Renal function (creatinine) of a second DA kidney transplanted 
into a “tolerised” PVG rat
“Tolerised” PVG rats were transplanted with a DA kidney following DSBT- 
pretreatment (1ml day -7 relative to transplant). >150 days later this graft was 
removed and replaced immediately with a second DA kidney (n=4). Regular blood 
samples were analysed for serum urea (Fig. 4.5) and creatinine (Fig. 4.6) post 
retransplant. Contralateral nephrectomy was performed 7 days after the first 
transplant and no further treatment was given other than retransplantation.
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Figure 4.7 Urea levels after transplantation of Lewis kidneys into “tolerised” 
PVG rats: rejection
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Figure 4.8 Urea levels after transplantation of Lewis kidneys into “tolerised” 
PVG rats: non-rejection
“Tolerised” PVG rats were transplanted with a DA kidney following DSBT- 
pretreatment (1ml day -7 relative to transplant). >150 days later this graft was 
removed and replaced immediately with a Lewis kidney (n=4). Regular blood 
samples were analysed for serum urea post retransplant. Contralateral nephrectomy 
was performed 7 days after the first transplant. Two rats rejected their grafts (Fig. 
4.7) whilst two rats survived for >50 days (Fig.4.8).
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to the Lewis graft after tolerising the PVG rat to a DA kidney by DSBT pretreatment. 
What is not clear from this experiment however, is whether this reflects some cross­
reactivity of the protective mechanisms to Lewis antigens or if there is a more 
generalised depression of the immune system in these long-term renal allografted 
rats. In contrast the remaining two rats in this experimental group failed to reject their 
Lewis allograft and both survived for >50 days. This suggests that these rats had 
developed a non-specific defect in their immune system. When the serum urea levels 
of these two rats were examined (Figure 4.8) a possible explanation became apparent. 
The first serum urea level measured post-operatively was markedly elevated. This 
implies that the renal function of the original allograft was declining and that the rats 
were markedly uremic at the time of the second transplant. The subsequent decrease 
in serum urea then witnessed lends support to the proposal of improved renal 
function upon transplant with a fresh kidney. The period of uremia post transplant 
may have played an immunosuppressive role and during this period the Lewis graft 
may have lost sufficient immunogenicity to allow long-term survival. This idea is 
analogous to the long-term graft acceptance seen following short term 
immunosuppression with cyclosporin A (Chapter 3, Section 3.2.1).
I l l
4.3.3 Organ specificity of DSBT-induced tolerance
Having demonstrated that DSBT-pretreated PVG rats were genuinely tolerant 
of DA renal allografts, the next objective was to determine whether tolerance was 
organ-specific or if it extended to other organs of the same donor MHC. This was 
investigated by grafting a heart onto the cervical vessels of PVG rats bearing 
longstanding DA kidneys by the method outlined previously (Chapter 2, Section 
2.2.4).
Four DSBT-pretreated PVG rats bearing DA kidneys were grafted with DA 
hearts and all 4 animals accepted the new organ with no evidence of acute rejection 
of either the original kidney or the new heart (Table 4.2). Having transplanted the 
kidney (7 days after a 1ml DSBT) approximately 100 days prior to the heart graft, no 
further treatment (except a contralateral nephrectomy on day 7 post renal transplant) 
was given either before or after the cardiac allograft. All cardiac grafts pulsed 
strongly for >100 days post transplant, and were still beating immediately prior to the 
termination of the experiment when the animals developed renal failure.
Adult thymectomised PVG rats were shown previously to accept DA renal 
allografts after a 1ml DSBT (Chapter 3, Section 3.2.4). As an extension of this, the 
ability of such rats to accept a subsequent heart transplant was investigated. Four 
adult thymectomised PVG rats bearing DA renal allografts (transplanted >50 days 
earlier, following DSBT-pretreatment) were grafted with either a DA heart or a third- 
party Lewis heart. The results are shown in Figure 4.9. All the donor-specific DA
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Table 4.2 Outcome of DA cardiac grafts in PVG rats tolerant of DA 
kidneys
Original renal graft 
(days)
Renal plus 
cardiac graft 
(days)
Survival of animal 
(days)
119 220 339
120 252 372
94 123 217
104 185 289
Tolerance to the original renal allografts (n=4) was induced by DSBT-pretreatment 
(lml day -7 relative to transplant). No additional treatment (except for a contralateral 
nephrectomy day 7 post renal transplant) was given either before or after transplant 
of the the cardiac allograft ~100 days later. Cardiac graft survival was assessed by 
daily palpation and absence of palpable pulsation defined as rejection.
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Figure 4.9 Outcome of heterotopic cardiac allografts in “tolerised” 
thymectomised PVG rats
Thymectomy was performed at least 6 weeks prior to the start of the experiment. 
“Tolerised” PVG rats were transplanted with a DA kidney following DSBT- 
pretreatment (1ml day -7 relative to transplant). Contralateral nephrectomy was 
performed 7 days later and >50 days after this a heterotopic cardiac transplant was 
performed with either a donor-strain (DA) or a third-party strain (Lewis) graft. All 
cardiac grafts were palpated daily and rejection defined as the absence of palpable 
pulsation.
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strain cardiac grafts were accepted, beating strongly for >100 days, whilst third-party 
Lewis heart grafts were rejected in <20 days. This indicated that the extension of 
tolerance to a subsequent heart transplant does not require the presence of an intact 
thymus and again confirms the peripheral nature of tolerance in this model. The 
prompt rejection of third-party (Lewis) hearts excludes non-specific 
immunosuppression as an effector mechanism for tolerance production.
Having observed that the tolerant state clearly extended to another 
vascularised organ graft, several PVG rats (tolerised to a DA kidney by DSBT- 
pretreatment) were grafted with full thickness DA skin grafts as described previously 
(Chapter 2, Section 2.2.5). The skin grafts exhibited prolonged graft survival 
although the donor skin was eventually rejected. Skin graft rejection in these rats 
bearing renal allografts was manifested by a gradual loss of hair followed by slow de- 
epithelialisation and scabbing of the graft rather than the rapid inflammatory response 
seen with skin grafts in naive rats. The precise end-point of these grafts (>80% graft 
loss) was often difficult to define. One rat skin grafted 3 months following renal and 
cardiac allografts (performed sequentially at three monthly intervals) showed 
especially slow loss of its skin graft with donor epithelium still visible 100 days later.
It is worth noting that the survival of cardiac allografts(>100 days) in these 
DSBT-pretreated and renal transplanted rats is considerably greater than donor- 
specific blood transfusion alone can achieve in this strain combination. This suggests 
that the long-term presence of the renal allograft itself is also influencing the
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outcome and correlates with the depressed alloreactivity of these rats suggested by 
the MLR data shown earlier (Figure 4.4).
4.3.4 Transfer of tolerance using splenocytes derived from long-term tolerant 
rats
If tolerance to an allograft is being maintained by an active mechanism then it 
should be possible in some instances to transfer tolerance by taking cells and/or 
serum from a tolerant rat and transferring these into a naive host which is then given 
an allograft with no further immunosuppression.
Q
Consequently, unseparated splenocytes (10 ) were transferred from a PVG rat 
that had borne a DA renal allograft (>100 days) to a naive PVG rat which was then 
immediately grafted with a DA rat kidney in the usual manner. A contralateral 
nephrectomy was performed on the second recipient 7 days post transplant. Using 
this protocol no evidence was seen for the existence of a cellular protective factor 
since all rats rejected their kidneys in 9 days (n=6) as for unmodified rejection in this 
strain combination. In a single instance 3.3 x 10 splenocytes were transferred (i.e. all 
the viable splenocytes from one “tolerised” rat) and the recipient survived for 12 
days. This increase in survival was minimal and the line of investigation was not 
pursued further.
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4.4 Discussion of the DA into PVG DSBT renal transplantation model
This series of experiments demonstrated that a single DSBT of 1ml of fresh 
whole DA blood exerts a profound influence on the immune system of the PVG 
recipient. Given 7 days prior to transplant, donor-specific prolongation of survival is 
seen in all cases with around 80% of rats surviving for >100 days without any further 
treatment.
In many of these DSBT-pretreated rats close monitoring of their renal 
function post transplant indicated that there is often a period of transient rejection 
approximately two weeks after grafting. The spontaneous resolution of this rejection 
may be partially attributed to graft adaptation following transplantation. The extent to 
which graft adaptation tends to protect the grafted organ is witnessed by the 
continued function of the kidney when retransplanted into a fresh host. This 
presumably corresponds to the loss of donor dendritic cells since other possibilities 
such as the transfer of suppressor cells within the graft are, although theoretically 
feasible, highly unlikely. One interpretation of the prolonged survival of these 
retransplanted kidneys is that the direct route of antigen presentation by donor 
dendritic cells is the main route for sensitisation in the PVG host and that indirect 
presentation of other antigens contained within these grafts is considerably less 
important.
The survival of cyclosporin A-treated rats (Chapter 3, Section 3.2.1), long 
after any effect of the drug has presumably worn off, may also be explained by graft 
adaptation. These cyclosporin A-treated rats would be expected to reject a second DA
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renal allograft (due to the dendritic cells within it) if graft adaptation is the sole 
reason for the prolonged survival of the original graft. It has also been proposed that 
dendritic cells themselves may influence the host immune system in a favourable 
manner, a concept known as donor-cell chimerism (Starzl et al, 1993). This theory 
suggests that donor-dendritic cells are in fact vital for tolerance production and are 
not merely a stimulus for rejector mechanisms. If this is the case then it would be 
predicted that rats receiving a “parked graft” would reject a subsequent further graft 
carrying dendritic cells, even if given a DSBT prior to their first transplant. Such 
experiments were not attempted but would be of great interest in a further study.
The immune system of PVG rats transplanted with DA kidneys following 
DSBT-pretreatment does clearly undergo considerable modification. When such 
PVG rats bearing long-surviving DA renal allografts (> 50 days) were retransplanted 
with a fresh donor-strain kidney there was no evidence of rejection despite the fresh 
dendritic cells contained within this kidney. Partial protection also extends however 
to third-party grafts but the degree of protection is less than to the original donor 
antigens, i.e. the DSBT effect is still specific in the long-term but to a lesser degree 
than in the short-term. This protective effect has been shown to extend to a second 
directly-vascularised organ, the heart, and also to indirectly-vascularised skin grafts 
albeit to a lesser degree. Whatever the mechanism producing this prolongation of 
graft survival it is clearly not tissue-specific although it is MHC type-specific.
Despite our lack of knowledge of the underlying mechanism for graft 
prolongation some information has come to light. The MLR data obtained suggested
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that some donor reactive cells were still present in the host LNC’s, otherwise an 
abolition of proliferation would have been anticipated. This would indicate that 
clonal deletion is unlikely as an effector mechanism in producing prolongation of 
graft survival. In experiments using adult thymectomised animals it was shown that 
the absence of the thymus had no effect upon tolerance production by DSBT- 
pretreatment i.e. the effect is peripheral rather than central. In addition, splenocyte 
transfer studies provided no evidence to suggest the existence of a cellular 
transferable factor capable of prolonging graft survival. It should be noted however 
that this was a stringent test capable of detecting such factors only if they were 
exerting a powerful effect. Evidence for the existence of such cellular factors has 
been advanced by several experimental groups in a variety of models. Using 
splenocytes from mice rendered tolerant of cardiac allografts following combined 
anti-CD4+ and anti-CD8+ monoclonal antibody therapy, Chen and coworkers (1993) 
were able to transfer tolerance to a naive mouse in a donor-specific manner in the 
absence of any additional therapy. Other workers have only been able to demonstrate 
such tolerance transfer if the new recipient was first treated with a sub-therapeutic 
dose of radiation (Hutcheson, 1986). Evidence for a serum transferable factor has 
been proposed by Kamada and coworkers (1986) who have shown that serum from 
DA liver grafted PVG rats is capable of specifically preventing rejection of (DA x 
PVG) FI heart grafts in naive PVG rats. In addition Chen and coworkers (1994) were 
able to show recovery of specific rejection following removal of a long-standing 
graft. This they attributed to the presence of the graft itself producing a state of
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chronic desensitisation as a consequence of prolonged engagement of host TCR’s by 
persistent alloantigens.
Graft adaptation corresponding to the loss of dendritic cells partly explains 
the prolonged survival of grafts in this model however, changes in the host’s immune 
system caused by both the DSBT and the graft itself are also important. The nature of 
these changes remain elusive.
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4.5 Summary
1 Depletion of passenger leukocytes in the transplanted kidney leads to 
prolonged survival and implies that indirect presentation is weak.
2 Longstanding transplanted kidneys are resistant to damage by 
infusions of sensitised lymphocytes implying that they are a poor 
target for rejector mechanisms.
3 The MLR of lymphocytes of animals bearing longstanding grafts is 
depressed implying that some unknown change in the host immune 
system is occurring.
4 Tolerised hosts will accept fresh kidneys in a strain-specific manner.
5 This tolerance is not organ-specific.
6 Thymectomy does not prevent DSBT induced tolerance to renal 
allografts subsequently extending to later heart allografts.
7 Tolerance was not transferable using splenocytes of animals bearing 
longstanding grafts when administered at the time of transplant.
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CHAPTER FIVE
The role of cytokines in rejection and donor-specific blood 
transfusion induced-tolerance in a low responder strain 
combination
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5.1 Introduction
Cytokines have a central role in the regulation of the immune response that 
occurs following organ transplantation. They are known to be involved in both the 
differentiation and proliferation of leukocytes (O’Garra, 1991a and b). In addition, it 
is now recognised that cytokines can cross-regulate each others production and 
function (Fiorentino et al, 1989; Llorente et al, 1989).
It has been very difficult to establish the precise function of individual 
cytokines in the immune response to an allograft due to the complexity of 
interactions taking place. In the past, bioassays have been employed to measure key 
cytokines such as interleukin-2 in both the blood stream and urine (Johnston et al, 
1990; Simpson et al, 1989) of renal transplant recipients. However, such bioassay 
techniques suffer from poor specificity and sensitivity and it is unclear to what degree 
these measurements reflect what is occurring within the graft.
Alternative methods of investigating cytokine production have utilised cell 
culture systems, often involving cloned cell lines. These have given a great deal of 
information as to the functions particular cytokines may perform but the true 
physiological role of a cytokine may be quite different from that seen in such 
artificial systems. In alloimmune responses there are potentially multiple cell types 
releasing a complex mixture of cytokines and the final outcome may be very difficult 
to predict. Furthermore some cytokine mRNA’s are reported to be highly unstable 
due to AU-rich sequences in their 3' untranslated regions which will cause the level
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of transcripts to decay rapidly if the stimulus for their continued production is lost by 
removal from the local environment (Shaw and Kamen, 1986).
The polymerase chain reaction (PCR) offers a method ideally suited to 
detection of relatively low levels of mRNA. Tissue is snap-frozen as soon as it is 
excised from the animal thereby ensuring that the mRNA extracted accurately 
reflects what is occurring within the tissue. The semiquantitative nature of the PCR 
performed in this study does not allow precise quantification of the absolute cytokine 
level to be made. It does however allow comparison of the relative level of individual 
cytokines to be made between tissues; differences of around tenfold are detectable 
(Dallman and Porter, 1991).
An alternative method of attempting to investigate the role of an individual 
cytokine in DSBT-induced tolerance is to administer the cytokine exogenously at the 
time of transplant and monitor the effect on the anticipated outcome. Some 
investigators believe that a deficit of IL-2 and/or IFN-y may be critical for tolerance 
induction by DSBT-pretreatment (Dallman et al., 1991; Bugeon et al., 1992). These 
workers have reported that both cytokines have the potential to restore rejection of 
allografts in models of DSBT-induced tolerance. Consequently we attempted to 
break DSBT-induced tolerance in the DA into PVG renal allograft model by 
intraperitoneal injections, of the recipient rat, with purified IL-2 and IFN-y cytokines 
in the post transplant period.
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5.2 Results
5.2.1 Cytokine mRNA levels in syngeneic, rejecting and enhanced renal grafts
Using the DA into PVG rat renal transplant model allogeneic grafts were 
examined at varying time points following transplantation in both naive (rejecting) 
and DSBT-pretreated (enhanced) recipients. In addition, normal non-transplanted 
kidneys and syngeneic grafts were also examined; the former to determine baseline 
cytokine mRNA levels and the latter to highlight any changes arising from the 
transplant operation itself. Syngeneic grafts were of PVG into PVG as the host 
immune system was then the same as in the allograft model.
Tables 5.1 to 5.4 show the individual results at each time point for the four 
cytokines tested. IL-2 and IFN-y were chosen as representative of a Thl response and 
IL-4 and IL-10 as representative of a Th2 response. Extra grafts were examined on 
day 4 as this time point appeared critical from the preliminary results.
In syngeneic PVG grafts low levels of IL-2 and IL-10 were detectable at all 
time points but no peak was noted. In contrast IL-4 and IFN-y were not detected at 
any time point. In normal DA kidney very low levels of IL-2 and IL-4 were detected 
however neither IL-10 or IFN-y were detectable.
When allografts were examined the following patterns emerged. IL-2 
transcript levels rose to a peak on day 4 post transplant and this rise appeared to be
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Tables 5.1 and 5.2 Levels of IL-2 and IFN-y (Thl cytokines) mRNA detected
by PCR in kidney tissue
Table 5.1 Interleukin-2
Time post 
transplant 
(days)
Syngeneic 
graft (PVG)
Rejecting 
allograft (DA)
Enhanced 
allograft (DA)
2 ND (+ ) ,  ' +
3 + > (+) + , ++ +» +
4 ND ++, +, ++, 
++  ++
(+)> +> ++, 
+
5 + » (+ ) +, +, ++ +, + , +
6 ND +> (+) (+ ) ,-
7 + , (+) +> (+) (+ ),(+ ),(+ )
21 ND NA +, +, +
100 (+ ) (+) NA (+), + , (+)
Table 5.2________________ Interferon-y
Time post 
transplant 
(days)
Syngeneic 
graft (PVG)
Rejecting 
allograft (DA)
Enhanced 
allograft (DA)
2 ND (+). (+) +
3 “j +, ++
4 ND ++, ++, ++, 
++, ++
+, +> 
++, ++
5 ++, ++,++ ++, H—1~5 ++
6 ND +, + +, +
7 "? (+), (+) +> ++, ++
21 ND NA +, ++, ++
100 NA -> (+)> -
Semiquantitative analysis of cytokine mRNA in fully disparate kidney allografts. DA grafts 
were excised on the days shown after transplant into naive or enhanced PVG rats. Enhanced 
allograft recipients received a 1ml DSBT 7 days prior to transplant. PCR for individual 
cytokine mRNA was carried out on neat cDNA and dilutions of 1/10 and 1/100, products 
were sampled at sequential 3-cycle intervals. Products were then gel electrophoresed, 
stained with ethidium bromide and viewed by UV transillumination. The level of mRNA 
present was scored as;
++ cytokine message detected at lowest cDNA concentration or cycle number 
+ cytokine message detected at intermediate cDNA concentration or cycle number 
(+) cytokine message seen only at highest cDNA concentration or cycle number 
cytokine message not detected at any cDNA concentration or cycle number 
NA not applicable as rejected grafts are destroyed by day 10. ND not determined
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Tables 5.3 and 5.4 Levels of IL-4 and IL-10 (Th2 cytokines) mRNA detected
by PCR in kidney tissue
Table 5.3 Interleukin-4
T i m e  p o s t  
t r a n s p l a n t  
( d a y s )
S y n g e n e i c  
g r a f t  ( P V G )
R e j e c t i n g  
a l l o g r a f t  ( D A )
E n h a n c e d  
a l l o g r a f t  ( D A )
2 N D + + ,  " + +
3 3 + >  ( + ) + + ,  -
4 N D ( + ) >  - >  + > ~ 3  ~ 3  " 3
5 3 ( + ) ,  ( + ) " 3  " 3
6 N D + + , - + + ,  -
7 3 + + >  - ( + ) >  - »  "
21 N D N A _ 3_ 3"
100 3 N A ( + ) .  ( + )
Table 5.4 Interleukin-10
T i m e  p o s t  
t r a n s p l a n t  
( d a y s )
S y n g e n e i c  
g r a f t  ( P V G )
R e j e c t i n g  
a l l o g r a f t  ( D A )
E n h a n c e d  
a l l o g r a f t  ( D A )
2 N D + >  ( + ) +
3 + > (  +  ) + »  + + >  +
4 N D + + ,  + ,  ( + ) ,  
+ ,  +
( + ) ,  ( + ) ,  
+ +
5 + >  (  +  ) + + 5 + + ,  + + + + ,  + ,  ( + )
6 N D + + ,  + + + >  ( + )
7 + >  - + + + ,  + ,  +
21 N D N A + > + >  ( + )
100 + >  + N A ” 3 ~ 3
Semiquantitative analysis of cytokine mRNA in fully disparate kidney allografts. DA grafts 
were excised on the days shown after transplant into naive or enhanced PVG rats. Enhanced 
allograft recipients received a 1ml DSBT 7 days prior to transplant. PCR for individual 
cytokine mRNA was carried out on neat cDNA and dilutions of 1/10 and 1/100, and 
products were sampled at sequential 3-cycle intervals. Products were then gel 
electrophoresed, stained with ethidium bromide and viewed by UV transillumination. The 
level of mRNA present was scored as;
++ cytokine message detected at lowest cDNA concentration or cycle number 
+ cytokine message detected at intermediate cDNA concentration or cycle number 
(+) cytokine message seen only at highest cDNA concentration or cycle number 
cytokine message not detected at any cDNA concentration or cycle number 
NA not applicable as rejected grafts are destroyed by day 10. ND not determined
127
reduced by DSBT-pretreatment (4/5 rejecting grafts exhibited high levels of 
transcript compared to 1/4 in the enhanced group). By day 6 however, even in the 
rejecting grafts these levels had fallen to that of syngeneic grafts.
These day 4 grafts were re-examined in a further experiment to try and 
confirm that this apparent difference was real and not an artefact produced by 
comparison of PCR reactions carried out on separate days. cDNA’s prepared from 
day 4 rejecting and enhanced grafts were examined in one PCR reaction at neat 
concentration only but over an extended range of 24,27,30,33 and 36 cycles of 
amplification. All products were then examined on a single gel (Figure 5.1). Message 
for IL-2 was consistently detected at cycle 24 in rejecting tissue but not until cycle 27 
in the enhanced tissue. This confirms that IL-2 transcript levels are higher in the 
rejecting tissues.
IFN-y was seen at high levels in both allogeneic groups, rejecting and 
enhanced, increasing from day three onwards. Interestingly in the enhanced grafts 
high levels continued to be detected on day 21 while in the rejecting grafts there was 
a fall after day 5 similar to that noted for IL-2. IL-4 and IL-10 were detectable in both 
the enhanced and rejecting groups but no consistent pattern was seen and no 
difference was apparent between the two groups.
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Day 4 Rejecting
cD N A  conc. 1/100 1/10 neat
cycle no. 1 5 2 0 2 5  1 5 2 0 2 5  1 5 2 0  25
(3 actin
-  + + + + ++
Day 4 Enhanced
1/100 1/10 neat
15 20 25 15 20 25 15 20 25 
.  .  +  .  +  +  +  +  + +
Interleukin-2
cycle no. 24 27 30 33 36
- F + + ++
24 27 30 33 36 
- - F + +
d*
F + + ++ F + +
F + + ++ F + +
Figure 5.1 Semiquantitative analysis of interleukin-2 mRNA in rejecting 
and enhanced kidney allografts 4 days post transplant
D A  grafts were exc ised  4 days after transplantation into naive or enhanced PVG  rats. 
Enhanced allograft recipients received a lm l D S B T  7 days prior to transplant. PCR for 
individual cytokine m R N A  was carried out on neat c D N A  prepared from individual 
allografts and products sampled at sequential 3 -cyc le  intervals. Products were gel 
electrophoresed, stained with ethidium bromide and v iew ed  by U V  transillumination. Note  
that faintly visib le  bands on U V  illumination (scored F) failed to appear on photographic  
reproduction. Gel electrophoresis o f  products from (3-actin PCR (top) performed on 3 
concentrations o f  c D N A  sh ow  bands at 5 -cycle  intervals that are equivalent in tolerant and 
rejecting tissue (e.g., grafts a* and d*) demonstrating the integrity o f  R N A  and c D N A  
preparation.
129
5.2.2 Attempts to abrogate DSBT-induced tolerance with exogenous IL-2 and
IFN-y
ExogenousIL-2
A total of 6 DSBT-pretreated rats were injected intraperitoneally with 3.6 x 
105 Cetus units of IL-2 on completion of the transplant operation and on days 1, 2,
3,4 & 5 post transplant. Contralateral nephrectomy was performed on day 7 post 
transplant. This dose of IL-2 was chosen as it had been found previously to 
completely abrogate the blood transfusion effect (Dallman et al., 1991).
Survival of these animals was 7, 9, 19, 36, 45 & 150 days. As the animal that 
died on day 7 post transplant had not undergone contralateral nephrectomy this death 
was not a consequence of rejection. DSBT-pretreatment alone in this strain 
combination was shown previously to result in >80% survival to 100 days with 
control survival time being <10 days (Chapter 3 Figure 3.4). It is clear from our 
results that addition of exogenous IL-2 (3.6 x 105 Cetus units) did not fully abrogate 
the effect of the earlier blood transfusion. Whilst there may be a reduction in the 
beneficial effect of the blood transfusion (only 1/6 survived to >100 days) it is 
difficult to draw any firm conclusion from the small number of rats involved. 
Unfortunately no further IL-2 was available to increase the number of rats treated or 
to try using higher dosages.
IFN-y
Similar experiments were performed using a limited amount of recombinant 
rat IFN-y. Rats were DSBT-pretreated 7 days prior to transplant and then injected on
the day of transplant and for 5 days afterwards with either 2xl05 international units 
(n=6) or 8x105 international units (n=3) of IFN-y.
This study was inconclusive. Three animals survived beyond the point where 
naive animals would have rejected their grafts (survival 18, 24 & 74 days). Of the 
other 6 animals whilst they died earlier (survival, 7, 9, 9, 9, 10 & 11 days) their grafts 
did not appear at post mortem to have undergone acute rejection and the suspicion 
was that these animals were succumbing to toxicity associated with IFN-y treatment 
rather than graft rejection. No dose dependent difference in outcome was apparent 
although the numbers involved were small. As in the IL-2 study this line of 
investigation was curtailed due to a lack of IFN-y.
5.3 Discussion of the role of cytokines in rejection and tolerance of allografts
A great deal of interest has been shown recently in determining the cytokines 
present within an allograft and postulating their role. This is partly a consequence of 
the division of T helper cells into subsets and the notion that one subset (Thl, 
including IL-2 and IFN-y) may be responsible for rejection whilst another (Th2, 
including IL-4 and IL-10) may function in tolerance induction (Lowry, 1993).
Using PCR it was established that only low levels of cytokine message for IL- 
2 and IL-10 were detectable in syngeneic renal grafts. In addition IL-4 and IFN-y 
were undetectable. Much higher levels of IL-2 and IFN-y were found in rejecting 
allografts. These findings concur with the literature and in particular that documented
for IL-2 (Morgan et al, 1993; Takeuchi et al, 1992) and IFN-y (Siegling et al, 
1994). Our results show that there is a peak in the level of IL-2 mRNA found in 
rejecting allografts at 4 days post transplant and these kinetics are in accordance to 
those published previously (Dallman et al, 1991; Bugeon et al, 1992). It has been 
shown in a murine cardiac allograft model that prior DSBT abrogates this peak 
(Takeuchi et al, 1992) and reduced levels of IL-2, on day 4 post transplant, were 
noted in our study, supporting the proposal that peripheral tolerance induced by 
alloantigen results from an alteration in the IL-2 pathway. The relative failure to 
restore rejection with exogenous IL-2 was not pursued exhaustively in the current 
study. We were able to show some reduction in the beneficial effect of DSBT 
pretreatment. Further work might involve the use of higher doses of IL-2. Osmotic 
minipumps might also be implanted to ensure adequate blood levels of IL-2 thereby 
avoiding the problem of using intermittent injections as IL-2 has a short half life.
In the present study the apparent similarity in the IFN-y transcript levels 
detected in both DSBT-enhanced and rejecting grafts is perhaps not surprising given 
that the main action of IFN-y is to upregulate MHC expression. DSBT itself is known 
to lead to a marked increase in MHC expression (Armstrong et al, 1987). Bugeon 
and coworkers (1993) have reported a reduction in IFN-y in addition to that shown 
for IL-2 following DSBT-pretreatment and suggest that MHC expression has become 
uncoupled from IFN-y in their model. In their study DSBT rats treated with 
exogenous IFN-y in fact showed accelerated rejection compared to the control group
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suggesting that IFN-y was doing more than merely abrogating the blood transfusion 
effect.
The presence of significant amounts of IL-4 and IL-10 in rejecting as well as 
enhanced grafts implies that these cytokines are not responsible for the tolerant state 
seen following alloantigen pretreatment. Lowry (1993) has proposed that IL-4 and 
IL-10 (Th2 like cytokines) may mediate specific unresponsiveness and presented 
evidence of long intragraft persistence of these cytokines however our experiments 
clearly do not lend support to this theory.
One criticism of PCR analysis of homogenates of intact grafts is that the 
source of the cytokines being measured can only be inferred and need not originate 
from either CD4 or CD8 lymphocytes. IL-4 can be produced by cells of the basophil 
and mast cell lineages (Plaut et al., 1989) and IL-10 can be produced by non­
lymphoid cells (Broski and Halloran, 1994). It is possible therefore that these non­
lymphoid cells are the source of the IL-4 and IL-10 message seen in rejecting 
allografts while in tolerised grafts the source is a tolerogenic lymphocyte. This would 
appear to be unlikely however given the similarity of the infiltrate seen when grafts 
from both groups were examined by immunohistochemistry. A definite answer to this 
question would require the in situ visualisation of the mRNA transcript concerned to 
permit the phenotype of the cytokine producing cell to be identified. This was 
attempted by in situ hybridisation using paraffin sections of formalin-fixed tissue but 
no successful specific labelling was achieved and this line of investigation was not 
pursued further.
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5.4 Summary
1 mRNA for interleukins-2,4, 10 and interferon-y were detectable using 
PCR technology in kidney tissues.
2 A rise in interleukin-2 transcript levels 4 days post transplant was seen 
in rejecting allografts.
3 DSBT-pretreatment reduces this rise suggesting an alteration in the 
interleukin-2 pathway is involved in tolerance induction by DSBT.
4 Interferon-y mRNA levels were raised in both enhanced and rejecting 
grafts to a broadly similar degree.
5 Exogenous interleukin-2 and interferon -y were both unable to fully 
break DSBT-induced tolerance.
6 No evidence was found to support the hypothesis that Th2 cytokines 
are tolerogenic as interleukin-4 and interleukin-10 were found at 
similar levels in rejecting and DSBT-enhanced grafts.
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CHAPTER SIX
A model of tolerance involving DSBT combined with cyclosporin A- 
pretreatment in two high responder rat strain combinations
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6.1 Introduction
One criticism of DSBT-induced tolerance is that it is restricted to specific 
strain combinations such as the low responder DA into PVG examined earlier. Other 
so called high responder strain combinations show little or no improvement in 
survival time when DSBT is used alone (Perloff and Barker, 1984; Robbins et al, 
1987). In these high responder strain combinations the use of a short course of 
immunosuppression in conjunction with DSBT-pretreatment has, in some cases, led 
to prolonged graft survival. Cyclosporin A has been used most commonly as a source 
of immunosuppression (Homan et al, 1981; Yasumura and Kahan, 1984) and 
therefore was employed in this study. FK506 has also been reported to have a similar 
effect (Fabrega et al, 1991). Cyclosporin A is widely used clinically and a 
combination of DSBT-pretreatment with cyclosporin A has been used in human 
cadaveric renal transplants. This appeared to cause a sustained reduction in the 
immunologic responsiveness to the donor antigens of the recipients (Alexander et al, 
1992).
Our initial studies employing combined immunosuppression and DSBT- 
pretreatment were carried out in the high responder R8 into RT1U strain combination. 
This combination was chosen as previous work in this laboratory had successfully 
used an anti-CD4 monoclonal antibody therapy to induce tolerance. We felt it was of 
interest to see if treatment involving donor antigen could also lead to tolerance 
induction and to compare this to the anti-CD4 model.
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In the PVG-R8 into PVG-RT1U strain combination only the class I MHC is 
mismatched i.e. the class II MHC and the minor transplantation antigens are 
identical. Allograft rejection in this strain combination can occur in the complete 
absence of measurable CD8+ cytotoxic T lymphocytes but the CD4+ T cell is 
essential for rejection (Gracie et al, 1990). It has also been demonstrated, by serum 
transfer experiments, that cytotoxic alloantibody alone can mediate graft destruction 
(Morton et al, 1993). Together these findings suggest that a major mechanism of 
graft destruction in this strain combination is cytotoxic alloantibody and the role of 
the CD4+ T cell is to provide help for the generation of this alloantibody.
The CD4+ T cell can only recognise antigen when presented in conjunction 
with the class II MHC molecule. In this purely class I-disparate strain combination 
the class II MHC molecules in the donor organ are syngeneic with the recipient and 
therefore incapable of initiating a rejection response directly. It is thought that the 
antigenic class I MHC molecules from the graft are internally processed by recipient 
antigen presenting cells and a series of peptides produced. These peptides are then 
expressed on the cell surface of the recipients own APC’s, in the peptide binding 
groove of host class II MHC molecules, where the CD4+ T cell can now recognise the 
presence of foreign antigens and mount a response against them. This is referred to as 
indirect presentation and is often assumed to be less efficient than the more 
conventional direct presentation via donor antigen presenting cells. However as 
rejection in this strain combination can proceed rapidly even if direct presentation to
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CD8+ lymphocytes by class I MHC has been prevented by anti-CD8 monoclonal 
antibody therapy this indirect presentation is clearly not always weak or inefficient.
In subsequent experiments we employed the fully disparate DA into Lewis 
combination to ensure that the results obtained were not unique to the R8 into RT1U 
model. This fully disparate strain combination is also high responder. Donor-specific 
blood transfusion alone has been found to have no beneficial effect on renal allograft 
survival (Wasowska et al., 1992) although an earlier report using affinity purified red 
blood cells did show some advantage (Wood and Morris, 1985).
6.2 Results: Development of a model of tolerance in a class I-disparate strain
combination (R8 into RT1U)
6.2.1 The effect of DSBT-pretreatment alone
DSBT-pretreatment alone was tested initially to see if any beneficial effect 
could be noted. A 1ml donor specific blood transfusion, when given 7 days prior to 
transplant, did not cause any increase in graft survival in this strain combination 
(Table 6.1). Increasing the number of transfusions to two or even four at weekly 
intervals was also ineffective at prolonging allograft survival with the mean survival 
time remaining ~9 days as for untreated controls.
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Table 6.1 Survival of RT1U rats transplanted with R8 kidneys following DSBT
DSBT
(days)
Recipient survival 
(days)
Mean survival time 
(days)
None 9,9,9,9,10 9
-7 9,9,9,9,9 9
-14,-7 9,9,9 9
-28,-21,-14,-7 9,9,10,10 9.5
DSBT (1ml R8 whole blood) was administered via the dorsal penile vein of the 
recipient rat (RT1U) on the days shown. All time points are relative to the day of 
transplant (R8 kidney day 0). Contralateral nephrectomy was performed on day 7 
post transplant.
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6.2.2 The effect of combined DSBT-pretreatment and perioperative anti-CD8 
treatment
As blood transfusion alone did not promote graft survival in the R8 into RT1U 
strain combination we chose to add the monoclonal antibody 0X8 to the treatment 
protocol. Although previous work in this strain combination has shown that the CD8+ 
T lymphocyte is not essential for rejection it did not exclude these cells as potential 
effectors. In this study, by excluding any contribution from these cells, any beneficial 
effect of blood transfusion masked by these cells would be exposed.
In addition to receiving donor-specific blood (1ml days -14 , -7, relative to 
transplant) three rats were treated with 0X8 (2mg intraperitoneal injection days -2, 0, 
+2, +4, +6). All rats were sacrificed on day 9 post transplant since they were showing 
severe signs of uremia. Immunohistology of the grafts was carried out to confirm the 
efficacy of the anti-CD8 treatment. Only a minimal infiltrate of CD8+ T lymphocytes 
was seen in the grafted kidney of rats treated with 0X8 despite widespread graft 
damage being present (Figure 6.1). The much higher CD8+ T lymphocyte infiltrate in 
unmodified rejection of an R8 kidney in an RT1U host is shown for comparison.
These results confirm that the CD8+ T lymphocyte is not essential for 
rejection in this strain combination and that a combination of anti-CD8 therapy and 
DSBT is ineffective at prolonging graft survival. This result concurs with the report 
that in H-2-recombinant MHC class I-disparate mice there are DSBT “resistant” 
CD4+ T cells that are capable of causing graft rejection (Kitagawa et al, 1991).
140
Figure 6.1 Inimunohistochemistry of R8 renal allografts in RT11 hosts
R8 kidneys were transplanted into RT11 host rats either unmodified or pretreated 
with 2 D S B T ’s ( lm l  days -14 & -7; relative to transplant) and 0 X 8  (2mg 
intraperitoneal injection days -2, 0, 2, 4 & 6). Grafts were removed for analysis 9 
days post transplant. Kidney tissue was snap frozen in liquid nitrogen and cryostat 
sections (5pm) were cut at -20°C onto gelatinised slides. Monoclonal antibodies were 
used to label the slides employing an indirect immunoperoxidase technique. Dense 
staining for 0 X 8  (CD8) is seen for the unmodified recipient (a) whilst minimal 
staining is evident for the pretreated recipient (b).
1 4 1
6.2.3 The effect of DSBT combined with short term cyclosporin A
Cunningham and coworkers (1988) have described a reduction in the 
complement-dependent cytotoxic antibody responses of F344 rats, following repeated 
weekly DA blood transfusions, if cyclosporin A is administered with the initial 
transfusion. Since antibody production has been shown to have a major role in 
causing acute allograft rejection in the R8 into RT1U strain combination (Morton et 
al., 1993) we thought that this treatment strategy might be effective in producing 
tolerance. Consequently, a variety of treatment protocols were tested in this strain 
combination based upon single or multiple blood transfusions (1ml) with or without 
an accompanying 7 day course of cyclosporin A (15mg/kg/day) starting at the time of 
the first transfusion (Table 6.2).
In contrast to rats receiving DSBT-pretreatment alone rats treated with a 
combination of cyclosporin A and 4 DSBT’s exhibited prolonged survival with 75% 
surviving >100 days post transplant. A single DSBT in association with cyclosporin 
A resulted in a moderate increase in graft survival (MST=50.5 days) however all 
grafts were rejected eventually. Cyclosporin A treatment alone also produced an 
increase in survival (MST=16.5 days) relative to control animals (MST=9 days). The 
tolerogenic effect of serial DSBT and cyclosporin A was found to be donor-specific 
since recipients receiving 4 third-party (PVG) blood transfusions and cyclosporin A 
all rapidly rejected R8 renal allografts (MST=10 days).
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Table 6.2 Survival of RT1U rats transplanted with R8 kidneys following blood 
transfusions with or without cyclosporin A
Pretreatment 
Blood transfusion Cy A 
(days) (days)
Survival
(days)
Mean survival time 
(days)
None None 9,9,9,9,10 9
R8 -28,-21,-14,-7 None *' 9,9,10,10 9.5
R8 -28,-21,-14,-7 -28 to -21 18,31,>100 (x6) >100
R8 -7 -7 toO 10,48,53,75 50.5
None 0 to 7 9,15,18,22 16.5
PVG -28,-21,-14,-7 -28 to -21 9,10,10,10 10
Blood transfusions (1ml whole blood) were administered via the dorsal penile vein of 
the recipient rat (RT1U) on the days indicated. All time points are relative to the day 
of transplant (R8 kidney day 0). Cyclosporin A (15mg/kg/day) was given by gavage 
once daily and contralateral nephrectomy was performed on day 7 post transplant.
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6.3 Results: DSBT combined with cyclosporin A in a fully disparate
high responder strain combination (DA into Lewis)
Initial experiments in this strain combination confirmed that DSBT alone had 
no positive effect on survival regardless if a single transfusion or multiple 
transfusions were administered prior to transplant (Table 6.3). If a 7 day course of 
cyclosporin A (15mg/kg/day) was incorporated at the time of the initial transfusion 
however, prolonged allograft survival resulted. This was shown to be the case for 
four transfusions in the first instance and subsequently the number of transfusions 
was reduced to two. Interestingly when two transfusions were employed the degree of 
increased survival was significantly reduced relative to that seen with four 
transfusions but remained well above the control group (Figure 6.2).
6.4 Discussion of the DSBT/cvclosporin A model of tolerance
A model has been developed in which cyclosporin A was used to influence 
the response to serial DSBT’s such that a state of tolerance to a later allograft was 
produced in two high responder strain combinations. This tolerance is clearly donor- 
specific as when third party blood transfusions are given then rejection occurs at the 
same rate as in naive rats. Tolerance was not due to the non-specific 
immunosuppressive actions of cyclosporin A since the transplant was performed 21 
days after cessation of treatment when any residual level of cyclosporin A would be 
extremely low. It was also shown in the R8 into RT1U combination that treatment
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Table 6.3 Survival of Lewis rats transplanted with DA kidneys following 
DSBT with or without cyclosporin A
Pretreatment 
DSBT (days) Cy A (days)
Survival
(days)
Mean survival time 
(days)
-7 None 9,9,9,9 9
-28,-21,-14,-7 None 9,9,9,9 9
-28,-21,-14,-7 -28 to -21 31,43,50,62,>100(x6) >100
-14,-7 -14 to -7 11,13,18,20,23,
25,31,48,100(x2) 24
Donor-specific blood transfusions (1ml DA whole blood) were administered via the 
dorsal penile vein of the recipient rat (Lewis) on the days indicated. All time points 
are relative to the day of transplant (DA kidney day 0). Cyclosporin A (15mg/kg/day) 
was given by gavage once daily and contralateral nephrectomy was performed on day 
7 post transplant.
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Figure 6.2 Effect of decreasing the number of DSBT’s used in conjunction 
with cyclosporin A on renal allograft survival (DA into Lewis)
Lewis rats were transplanted with DA kidneys 7 days after pretreatment with 
donor-specific blood transfusions and cyclosporin A. DSBT’s (1ml) were given at 
weekly intervals for either 4 or 2 weeks prior to transplant. Cyclosporin A 
(15mg/kg/day) was given by oral gavage once daily, after the initial blood transfusion 
only, for 7 days. Unmodified rejection time is shown for animals that did not receive 
any form of treatment. Contralateral nephrectomy was carried out on day 7 post 
transplant.
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with cyclosporin A alone, for 7 days starting at the time of transplant, was 
insufficient to produce the prolongation in survival seen following combined 
DSBT/cyclosporin A therapy. Such animals did however show a modest survival 
advantage over the control groups.
It is of note that in the DA into Lewis strain combination four DSBT’s 
appeared to confer increased benefit compared to two DSBT’s. This was despite the 
greater time elapsed between administration of cyclosporin A and the transplant. 
There are two possible explanations. Repeated antigenic challenges in the form of 
DSBT’s may serve to reinforce the developing tolerant state. Alternatively, the 
tolerant state may develop slowly and hence the increased time period between the 
cyclosporin A treatment and the transplant itself may be responsible for the improved 
outcome rather than the repeated antigenic challenges. This latter explanation is in 
keeping with the report that specific tolerance induced with donor antigens and anti- 
CD4 monoclonal antibody is seen at 28 days post transfusion (Pearson et al, 1992).
The combination of repeated DSBT’s and a short course of cyclosporin A, 
started at the time of the first transfusion, is capable of consistently producing long­
term graft acceptance in strain combinations where neither treatment alone is 
effective.
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6.5 Summary
1 DSBT-pretreatment alone does not increase allograft survival in either 
of the high responder strain combinations tested.
2 Anti-CD8 treatment in addition to DSBT does not improve allograft 
survival in the R8 into RT1U strain combination.
3 Serial DSBT’s at weekly intervals with the addition of a 7 day course 
of cyclosporin A (15mg/kg/day) started with the first transfusion 
markedly prolonged survival in both high responder strain 
combinations.
4 Increasing the number of DSBT’s from two to four increased the 
beneficial effect on graft survival in the DA into Lewis strain 
combination.
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CHAPTER SEVEN
Investigation into the mechanism of DSBT/cyclosporin A- 
induced tolerance
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7.1 Introduction
Having developed a model of DSBT/cyclosporin A-induced tolerance to renal 
allografts in two high responder rat strain combinations (Chapter 6) we investigated 
the nature of this phenomenon. It was of considerable interest to see how the results 
of these investigations compared to those obtained previously for the DA into PVG 
low responder strain combination (Chapter 4).
As this model had not been studied previously preliminary investigations 
involved examination of the cellular infiltrate in rejecting and non-rejecting grafts. 
Subsequently a series of retransplantation experiments were carried out to assess the 
degree of graft adaptation occurring in this model and also the extent of the tolerance 
achieved. Earlier experiments in the DA into PVG model showed clearly that the 
presence of the thymus was not required for tolerance induction following a single 
DSBT. Since DSBT alone does not lead to tolerance induction in either the DA into 
Lewis or the R8 into RT1U strain combinations it is possible that the mechanism 
involved may differ and might potentially involve the thymus. Cyclosporin A has 
been reported to lead to a dramatic increase in circulating recent thymic emigrants 
(Zadeh and Goldschneider, 1993), and it has also been suggested that these recent 
thymic emigrants may be more easily rendered tolerant than mature peripheral T 
cells. For these reasons it was considered worthwhile to question the role of the 
thymus in this model.
Cytotoxic alloantibody is believed to be a major cause of acute graft rejection 
in the R8 into RT1U strain combination (Morton et al, 1993) and as such this
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antibody titre should correlate closely with survival. Simple DSBT-induced 
enhancement of renal allograft survival (e.g. the DA into PVG model) has been 
shown to correlate with host MHC-linked inhibition of IgG anti-donor class I 
alloantibody (Wasowska et al., 1993). In our model however, DSBT alone did not 
enhance graft survival unless cyclosporin A was also administered at the time of the 
first transfusion. The use of such combinations of DSBT and cyclosporin A has been 
shown to be effective in reducing cytotoxic alloantibody in strain combinations 
where DSBT alone is ineffective, although the study concerned did not attempt to 
establish any beneficial effect on vascularised organ grafts (Jones et al., 1988). The 
level of cytotoxic alloantibodies was also measured in the DA into Lewis model. 
This was done to monitor the way in which antibody titres vary during tolerance 
induction in a strain combination where a role for cytotoxic alloantibody in acute 
rejection is less well established.
Antibody levels following blood transfusion alone were examined in adult 
thymectomised rats to determine if the presence of an intact thymus gland exerted 
any effect on antibody responses in these high responder strain combinations. In 
addition the IgM and IgG subclasses of anti-RTl Aa antibody were studied in detail to 
assess whether any selective effect on individual alloantibody isotypes was 
identifiable.
Having carried out a detailed examination of cytokines detectable in grafts of 
DSBT-treated PVG rats transplanted with DA kidneys (Chapter 5), it was of great 
interest to see if the pattern obtained in these high responder rats was similar given
the greater role of antibody mediated graft destruction in this model. Several studies 
have reported important differences in cytokine expression between tolerant and 
rejecting organ allografts and this has given rise to the concept that transplant 
tolerance may, in part, be explained by polarisation of the alloreactive T helper 
response from a Thl to a Th2 cytokine profile (Takeuchi et al., 1992; Seigling et al., 
1993; Ferraresso et al., 1994; Chen and Field, 1995). As before, semi-quantitative 
RT-PCR was employed to examine the presence of mRNA transcripts for Thl and 
Th2 cytokines in rejecting and non-rejecting grafts. Due to the limited number of 
animals available (animals were bred in-house from a small number of breeding 
pairs) a single timepoint of day 5 post transplant was studied. Spleens were also 
examined as antibody production need not be an intragraft event. It remains possible 
that events in the spleen may have a bearing on the outcome in this model.
7.2 Results
7.2.1 Analysis of the cellular infiltrate in rejecting and non-rejecting R8
renal allografts in R Tl11 recipients
R8 kidneys were examined microscopically 5 days after transplant into either 
naive RT1U rats or those pretreated with DSBT/cyclosporin A. In the case of 
unmodified recipients there was a heavy interstitial cell infiltrate, widespread 
vascular damage, focal tubular necrosis and glomerular ischaemia. By day 7 this had 
progressed to extensive interstitial haemorrhage and often complete infarction. In
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contrast, R8 grafts from RT1U recipients rendered tolerant by serial DSBT and 
cyclosporin A showed minimal evidence of renal parenchymal damage although 
there was still a dense mononuclear cell infiltrate.
Closer examination of the magnitude and phenotype of these cellular 
infiltrates was determined by morphometric analysis of immunoperoxidase labelled 
cryostat sections. The results are shown in Table 7.1. Both rejecting and non­
rejecting grafts were infiltrated to a similar degree by a dense mononuclear cell 
infiltrate consisting mainly of macrophages distributed diffusely throughout the 
interstitium of the kidney. In both groups there were substantial numbers of CD8+ 
cells although the distribution was different. In rejecting grafts the CD8+ cells tended 
to be focally distributed perivascularly (and to a lesser extent periglomerularly) while 
the non-rejecting grafts contained a more diffuse CD8+ infiltrate. Interestingly non­
rejecting grafts contained approximately fourfold more CD4+ cells, distributed 
diffusely throughout the kidney, than the rejecting grafts. 0X 39+ cells were readily 
visible in rejecting grafts but were almost undetectable in non-rejecting grafts, in 
keeping with a reduced state of cellular activation. The mAb 0X39 is directed 
against an epitope on the low affinity (p55a) chain of the IL-2 receptor, seen 
principally following cell activation (Paterson et al, 1987).
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Table 7.1 Cellular infiltrate in class 1 Aa-disparate R8 kidney allografts in 
RT1U recipients
Percentage area occupied by infiltrate
CD45 CD8 CD4 ct(3TCR M 0 IL-2R
Unmodified 21±9 7±4 2±2 6±3 13±3 3±3
rejection (100%) (33%) (10%) (29%) (62%) (14%)
Tolerant 25±9 10±6 9±3 9±4 20±9 <1
(BT + CyA) (100%) (40%) (36%) (36%) (80%) (<5%)
Tolerance to a R8 kidney was achieved by pretreating RT1U rats with four 1ml 
DSBT’s at weekly intervals (days -28, -21, -14, -7 relative to transplant) together 
with cyclosporin A (15mg/kg/day) for 7 days after the first DSBT (days -28 to -21). 
Kidneys were excised from tolerised recipients and also from unmodified recipients 5 
days post transplant and snap frozen. Cryostat sections from these kidneys were 
labelled using the immunoperoxidase technique. The percentage area infiltrate was 
determined by point counting with a microscope eyepiece graticule. Values shown 
are the mean ± SD of 4 allografts. Results in parentheses represent the phenotype as 
a percentage of the total area of cellular infiltrate ( i.e. percentage of CD45 infiltrate). 
afTC R  = T cell receptor, M0=macrophage, IL-2R= interleukin-2 receptor.
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7.2.2 Retransplantation experiments in the R8 into RT1U strain combination: 
second renal allografts of rats tolerant of an initial R8 kidney
Four RT1U rats bearing a longstanding R8 renal allograft (>100 days) were 
grafted with a fresh R8 kidney and at the same time the original graft was excised. 
These rats all survived for >100 days. This result showed that the long-term survival 
of the original graft was not simply due to graft adaptation and suggested that the 
host immune system had been tolerised towards R8 antigens. Unfortunately no third- 
party grafts were carried out to ensure that these animals were still capable of 
mounting an immune response against non-specific alloantigens hence caution is 
required in interpreting this result. It would appear however that DSBT combined 
with cyclosporin A does lead to tolerance of renal allografts in this model.
7.2.3 Retransplantation experiments in the R8 into RT1U strain combination: 
transplantation of grafts from tolerised rats into fresh naive hosts
As a test for graft adaptation R8 kidneys that had been resident in RT1U hosts 
for >100 days were retransplanted into naive RT1U rats. This was carried out in a 
group of four rats which underwent contralateral nephrectomy 7 days post transplant. 
Of this group, three rats died 9 days post transplant; inspection of the grafts at post 
mortem showed severe rejection. The remaining rat survived >100 days with normal 
renal function. It is unclear why this one animal should have a different outcome 
from the others. Rejection of “parked” grafts, at a similar rate to normal allografts 
would suggest that passenger leukocyte depletion, by “parking” in tolerised hosts,
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does not usually lead to prolonged graft survival in the R8 into RT1U strain 
combination. This result differs from the DA into PVG study (Chapter 4, Section 
4.2.1) where all “parked” grafts showed markedly prolonged survival (mean >100 
days).
7.2.4 The role of the thymus in DSBT/cyclosporin A-induced tolerance
Thymectomised rats were pretreated with four 1ml DSBT’s (days -28,-21,-14, 
& -7 relative to transplant) and cyclosporin A (15mg/kg/day, days -28 to -21). All 
rats were thymectomised at least 4 weeks prior to the first transfusion. Both high 
responder strain combinations (R8 into RT1U and DA into Lewis) were examined. A 
total of four RT1U and five Lewis rats were treated in this experiment, survival times 
are shown in Table 7.2. Whilst it is possible that there was some reduction in the 
degree of prolongation of survival in the case of the thymectomised R8 into RT1U 
rats (survival of DSBT/cyclosporin A-pretreated non-thymectomised rats was shown 
in Chapter 6 to be 80% at 100 days) only small numbers were involved. It is clear 
however that in both strain combinations elimination of the thymus does not prevent 
DSBT/cyclosporin A-pretreatment prolonging allograft survival relative to that 
obtained in thymectomised but otherwise unmodified rats (survival <10 days in both 
strain combinations). This would suggest that a peripheral mechanism is responsible 
for the beneficial effect of DSBT/cyclosporin A-pretreatment in this model.
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Table 7.2 Survival following transplant of adult thymectomised rats 
pretreated with 4 DSBT’s and cyclosporin A
Strain combination Survival (days)
R 8/R T 1U 14*, 20,42, >100
DA/Lewis 12, 39,93,103, >150
Thymectomy was performed at approximately 6 weeks of age and rats were not used 
for at least a further four weeks. All recipient rats received four 1ml DSBT’s (days 
-28,-21,-14,-7, relative to transplant) and cyclosporin A (15mg/kg/day, days -28 to 
-21) by gavage. Contralateral nephrectomy was performed 7 days post transplant.
* This animal died due to an infrarenal abscess secondary to a ureteric leak and the 
graft appeared healthy at post mortem. Death was unlikely to be due to rejection.
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7.2.5 The role of cytotoxic alloantibody in DSBT/cyclosporin A-induced
tolerance
R8 into RT1U
As can be seen in Figure 7.1 animals transfused in the absence of cyclosporin 
A show very high cytotoxic alloantibody titres which do not appear to decrease with 
repeated transfusion. When cyclosporin A was added to the protocol there was still a 
measurable response to the first transfusion but it was smaller and with repeated 
transfusions the titre fell almost to zero. Following grafting a very small rise in 
cytotoxic alloantibody was noted in some cases but this returned to zero. A late rise 
in antibody titre was exhibited by one rat that died 30 days post transplant. In general, 
low cytotoxic antibody levels are associated with prolonged graft survival as would 
be expected in a model where such an antibody is believed to cause acute graft 
damage.
The decline in cytotoxic alloantibody responses following tolerance induction 
by serial blood transfusion and cyclosporin A treatment was clearly demonstrated to 
be independent of the thymus gland (Figure 7.2). Rats having undergone thymectomy 
30 days prior to transfusion and cyclosporin A treatment showed similar responses to 
rats having undergone only sham thymectomy.
The class and subclass of circulating anti-class I antibody in recipients of R8 
renal allografts were determined by flow cytometric analysis (Figure 7.3). Whereas 
serum from unmodified recipients contained anti-class I antibodies of IgM and of 
IgGl, IgG2a and IgG2b isotypes, serum from tolerant animals contained minimal 
IgM alloantibody or IgG antibody of any subclass.
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Figure 7.1 Circulating cytotoxic RTlAa antibody responses in RT1U rats 
to serial R8 blood transfusions followed by a R8 renal allograft
RT1U rats were given a series of four 1ml transfusions of R8 blood (DSBT) at 7 day 
intervals (arrows) followed by a R8 renal allograft on day 0. Recipients were given 
either DSBT alone or DSBT together with cyclosporin A (15mg/kg/day) for 7 days 
following the initial DSBT.Contralateral nephrectomy was carried out day 7 post 
transplant. Sera were assayed against 51Cr-labelled R8 Con A blasts in the presence 
of guinea pig complement. Values shown are the mean of 4 rats +/- SD.
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Figure 7.2 Circulating cytotoxic RTlAa antibody responses in thymectomised 
and sham thymectomised RT1U rats to serial R8 blood transfusions
RT1U rats both thymectomised and sham thymectomised were given a series of three 
lml transfusions of R8 blood (BT) at 7 day intervals (arrows). Recipients were given 
either R8 blood alone or together with cyclosporin A (15mg/kg/day) for 7 days 
following the initial transfusion. Sera were assayed against 51Cr-labelled R8 Con A 
blasts in the presence of guinea pig complement. Values shown are the mean of 4 rats 
+/- SD.
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Figure 7.3
log3 reciprocal serum dilution
Circulating anti-RTlAa antibody responses in RT1U rats 7 days 
after receiving a R8 renal allograft
Graft recipients were either unmodified (naive) or had been rendered tolerant 
(“tolerised”) by four 1ml DSBT’s at 7 day intervals (days -28, -21, -14, -7 relative to 
transplant) together with cyclosporin A (15mg/kg/day) for 7 days after the first DSBT 
(days -28 to -21). The subclass and isotype of Ig were determined by flow cytometery 
using R8 lymph node cells as targets and mouse anti-rat Ig-specific monoclonal 
antibodies. Values shown are the mean of 3-4 rats +/- SD.
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DA into Lewis
A role for cytotoxic alloantibody in acute rejection is not so clearly 
established in this strain combination. Cytotoxic alloantibody levels were shown to 
correlate however with the failure of a single DSBT to cause any positive effect in 
terms of graft survival. Figure 7.4 demonstrates that a single blood transfusion 7 days 
prior to transplant stimulates a strong response as measured by cytotoxic alloantibody 
titre. Grafts at this point are rapidly destroyed (Table 6.3) and the antibody titre 
remains high. While this does not prove that cytotoxic alloantibody is an important 
effector mechanism in this model (this would necessitate showing that serum transfer 
from rats bearing rejecting grafts could cause acute damage to stable grafts in a 
second tolerised rat) it does at least suggest that alloantibody may act as a marker of 
activation of the host immune system.
Repeated blood transfusions alone do not appear to lead to any significant 
decrease in antibody titre and grafts continue to be rapidly rejected (Figure 7.5). As in 
the previous R8 into RT1U experiments, the addition of a short course of cyclosporin 
A at the time of the initial transfusion resulted in a much smaller rise in antibody titre 
that declined dramatically despite further antigenic challenges in the form of either 
blood or a graft. These grafts went on to enjoy long-term survival.
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Figure 7.4 Circulating cytotoxic alloantibody responses in Lewis rats to a DA 
blood transfusion followed by a DA renal allograft
Lewis rats were given a 1ml transfusion of DA blood (DSBT arrow) followed 7 days 
later by a DA renal allograft. Contralateral nephrectomy was carried out day 7 post 
transplant. All rats were sacrificed on day 9 due to having developed severe uremia 
secondary to graft rejection. Sera were assayed against 51Cr-labelled DA Con A 
blasts in the presence of guinea pig complement. Values shown are the mean of 4 rats 
+/- SD. There was no lysis of third-party PVG target cells (data not shown).
163
— » DSBT + CyA 
^=»- DSBT
1 0
V  D S B T
8
< 1
6
4
2
0
- 3 0 -20 O 10 20- 1 0
D a y s  r e l a t i v e  to  t r a n s p l a n t
Figure 7.5 Circulating cytotoxic alloantibody responses in Lewis rats to 
serial DA blood transfusions followed by a DA renal allograft
Lewis rats were given a series of four 1 ml transfusions of DA blood (DSBT) at 7 day 
intervals (arrows) followed by a DA renal allograft on day 0. Recipients were given 
either DSBT alone or DSBT together with cyclosporin A (15mg/kg/day) for 7 days 
following the initial DSBT. Contralateral nephrectomy was carried out day 7 post 
transplant. All rats that received DSBT-pretreatment alone were sacrificed on day 9 
having developed severe uremia secondary to graft rejection. Sera were assayed 
against 51Cr-labelled DA Con A blasts in the presence of guinea pig complement. 
Values shown are the mean of 4 rats +/- SD. There was no lysis of third-party PVG 
target cells (data not shown).
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7.2.6 Cytokine mRNA levels in renal allografts and spleens of tolerised
and naive rats 5 days post transplant. R8 into RT1U
The presence of cytokine mRNA in class I-disparate kidney allografts 5 days 
post transplant was determined by semiquantitative RT-PCR (Table 7.3). Message 
for IL-2 and IFN-y was detected at essentially similar levels in tolerant and rejecting 
allografts. Message for IL-4 and IL-10 was readily detected in the rejecting grafts but 
was barely present in the tolerant allografts of the DSBT/cyclosporin A-pretreated 
rats. The significance of this striking difference is discussed later.
The presence of cytokine mRNA in the spleens of those rats receiving class I- 
disparate kidney allografts was also determined by semiquantitative RT-PCR 5 days 
post transplant (Table 7.4). Message for IL-2 and IFN-y was detected at broadly 
similar levels in the spleens of rats bearing either rejecting or tolerant grafts and 
similar levels were also detected in spleens removed from naive RT1U rats. IL-10 
transcript was detected at low levels in the spleens of rats bearing rejecting kidneys 
but was found in none of the rats bearing tolerant kidneys. Where detectable, levels 
were substantially lower than those seen in the actual grafts themselves. Message for 
IL-4 was detected at varying levels in the spleens of most rats tested but there was no 
clear pattern and the significance of the IL-4 transcript in the spleen is unclear.
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Table 7.3 Semiquantitative analysis of cytokine mRNA in class I-disparate
kidney allografts
p actin
c y c le  no. 15 20 25 15 20 25 15 20 25 15 20 25 15 20 25 15 20 25
IL-2
IFNy
tolerant rejecting
24 27 30 33 36 24 27 30 33 36
a 
b 
* c 
d
-  +  
-  +
-  +
+ + 
+ + 
+ + 
+ +
e - 
f -
g  •
h -
- +  +  +
- +  +  +
- + +  +
24 27 30 33 36 24 27 30 33 36
a + + + + + e + + + +  +
b - +  + + + f - - + +  +
* c  + + + + +  g + +  + + + *
d + + + + + h - + +  + +
tolerant rejecting
IL-4
.
29 32 35 38 41 29 32 35 38 41
a
*b
c
d
e + + + + + *
f - + + + +
g - - - + +
h - + + + +
IL-10
a - 
* b - 
c - 
d -
34 37 40 43 46 
-  +
34 37 40 43 46
e - 
f -
g  -
h -
+ + +
+ + +
+ + +
+ +  +  *
R8 grafts were excised 5 days post transplant into unmodified R T l lJ recipients 
(rejecting) and recipients pretreated with 4 R8 D SB T ’s together with cyclosporin A 
for 7 days following the first DSBT (tolerant). Results are shown for 4 tolerant (a-d) 
and 4 rejecting (c-h) kidney allografts.
PCR for individual cytokine mRNA was performed on neat cDNA prepared 
from each allograft (a-h) and products sampled at sequential 3 cycle intervals. 
Products were gel electrophoresed stained with ethidium bromide and viewed by UV 
transillumination. The presence (+) or absence (-) o f  a visible band was then recorded 
for each cycle number sampled. Note that at the lowest cycle numbers bands visible 
with UV and scored present (+) failed to appear on photographic reproduction. 
Asterisks identify individual tolerant and rejecting grafts for which gels o f  cytokine 
PCR reactions are shown. Gel electrophoresis o f  products from P-actin PCR (top) 
performed on 3 concentrations o f  cDNA show bands at 5-cycle intervals that are 
equivalent in tolerant and rejecting tissues (e.g., grafts d and g) demonstrating the 
integrity o f  RNA and cDNA preparation.
tolerant (rat d) rejecting (rat g)
i 1 i------------------------------------------------------------------------------1
1/100 1/10 neatcDNA 1/100 1/10 neat cDNA
i----------------------------1 i--------------------------- 1 i----------------------------1 i----------------------------1 i--------------------------- 1 i---------------------------- 1
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Table 7.4 Semiquantitative analysis of cytokine mRNA in spleens of rats
receiving class 1-disparate kidney allografts
IL-2 IL-4
Tolerant Rejecting Tolerant Rejecting
cycle no 2 4  2 7  3 0  3 3  3 6 2 4  2 7  3 0  33 3 6 cycle no 2 9  3 2  3 5  3 8  41 2 9  3 2  3 5  3 8  41
a e _ + a - - - +  + e j j j +
b - - - - | + f - b - - + +  + f - + + + +
c _ . _ . + g - - - - + c _ + + + + g
d . _ .  . + h - - - - + d - - - - + h - - - - +
IFN-y IL-10
cycle no 24 27 30 33 36 24 27 30 33 36 cycle no 34 37 40 43 46 34 37 40 43 46
a - -  - + + e -  -  + + + a ............................ e _ .  .  _ +
b - -  + + + f -  -  + + + b - - - - - f -  -  -  -  +
c - -  + + + g -  -  - + + c -  -  -  -  - g
_ .  .  .  +
d - -  - + + h -  -  - + + d - - - - - h .  _  .  .  +
Spleens were excised 5 days post transplant o f  R8 renal allografts into unmodified 
RT11 recipients (rejecting) and recipients pretreated with 4 R8 D S B T ’s together with 
cyclosporin A for 7 days following the first DSBT (tolerant). Results are shown for 4 
rats bearing tolerant (a-d) and 4 rat bearing rejecting (e-h) allografts.
PCR for individual cytokine m RNA was performed on neat cDNA prepared 
from each spleen (a-h) and products sampled at sequential 3 cycle intervals. Products 
were gel electrophoresed stained with ethidium bromide and viewed by UV 
transillumination. The presence (+) or absence (-) o f  a visible band was then recorded 
for each cycle number sampled.
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7.3 Discussion of the DSBT/cyclosporin A-induced model of tolerance in a 
class I-disparate rat renal allograft model
Using a pretransplant protocol comprised of 4 serial DSBT’s combined with a 
7 day course of cyclosporin A (given with the first DSBT) we were able to achieve 
long-term donor-specific renal allograft acceptance without the need for further 
treatment. The humoral and intragraft cellular events that accompany induction of 
tolerance by this protocol are of considerable interest since little is known in a model 
where alloantibody plays a key role in effecting acute rejection.
Microscopic analysis of the cells infiltrating these allografts 5 days post 
transplant showed that both rejecting and tolerant grafts were heavily infiltrated by 
mononuclear cells, including numerous CD4+ and CD8+ cells, although the 
distribution varied between the rejecting and tolerised grafts. In addition the virtual 
absence of 0X3 9+ cells (IL-2R) in tolerant grafts suggested a reduced state of cellular 
activation. No attempt was made in this study to determine the in vitro cytotoxic 
activity of these graft infiltrating cells as previous work had shown that the graft 
infiltrate from rejecting R8 grafts displays minimal cytotoxicity for R8 target cells 
(Gracie et al, 1990).
The retransplantation of tolerised rats with fresh kidneys demonstrated that 
this protocol produced genuine tolerance as R8 kidneys showed long-term survival. 
The rapid rejection (3/4) seen when longstanding “parked” grafts were retransplanted 
into naive RT1U rats suggests that graft adaptation is minimal but prolonged survival 
is due to changes occurring within the host.
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One interpretation of the rapid rejection of “parked” grafts is that the RT1U 
host’s immune system is capable of processing the antigens remaining within the 
grafts and mounting an effective immune response without requiring professional 
antigen presenting cells (dendritic cells) contained in a fresh graft. This requires that 
the RT1U APC’s are capable of presenting graft antigens (class I MHC derived as 
other transplant antigens are identical in this strain combination) to the effector cells 
involved in graft destruction. This in turn implies that there is an effective route of 
indirect presentation of graft antigens in this model. An alternative, but perhaps less 
likely, explanation might be that there are still donor-derived APC’s present in the 
graft following its period of residence in the primary host. The marked prolongation 
of survival of “parked” grafts in the DA into PVG model studied earlier (Chapter 4, 
Section 4.2.1) suggests that such indirect presentation is of little consequence in that 
particular model. The idea that the relative contributions of the direct and indirect 
routes of antigen presentation to rejection, may be responsible for the strain- 
dependent efficacy of DSBT-pretreatment protocols has been proposed previously 
(Parker et al, 1992). Further work using T cell clones has suggested that indirect 
presentation is favoured if the class II MHC of the donor and recipient are well 
matched (Chen et al., 1990). Clearly the common class II antigens of the congeneic 
rats used in this model fit this hypothesis very well. Retransplantation experiments in 
the DA into Lewis strain combination were not examined although it would be of 
interest to see which pattern they would follow.
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As in the earlier study of DSBT-induced tolerance in the DA into PVG model 
this DSBT/cyclosporin A-induced tolerance appears to be peripheral in nature, 
despite the fact that cyclosporin A is known to have a central effect on the thymus 
gland. This finding is potentially important since the human adult thymus is believed 
to be much less immunologically active than the rodent thymus. Consequently a 
mechanism of tolerance that required an active thymus would be less likely to be 
significant in a clinical environment. Both models of transplantation tolerance 
discussed in this work are independent of the thymus and thus may be suitable for the 
clinical setting.
Given the known ability of cytotoxic alloantibody to destroy Aa-disparate 
grafts in RT1U recipients, it was not surprising that tolerance induction by serial 
DSBT and cyclosporin A was associated with abrogation of circulating cytotoxic 
alloantibody. Exposure of the recipient’s immune system to DSBT, initially in the 
presence of cyclosporin A, appears to lead to a reduced production of all subclasses 
of IgM and IgG in response to further challenge with repeated DSBT’s and a renal 
allograft. The absence of circulating anti-class I alloantibody could, in theory, be due 
to either B cell tolerance or to impairment of CD4+ T cell help. The principle site of 
action of cyclosporin A is the T helper cell where it appears to prevent clonal 
expansion of activated T cells (Granelli-Pipemo, 1990). Exposure of the recipient’s 
immune system to donor alloantigen in the absence of appropriate CD4+ T cell help 
is likely to play a key role in tolerance induction in this model. Further studies might 
involve the transfer of CD4+ T cells from tolerant animals into congenitally athymic
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nude RT1U rats (which have an intact B cell pool) to see if they provide help for 
rejection of Aa-disparate allografts.
Previous studies involving DSBT’s and cyclosporin A have raised the 
possibility of suppressor cells (Jones et al, 1988) or the involvement of anti-idiotypic 
antibodies (Cunningham et al, 1988). These proposals were not considered in the 
current study and would be of interest for future investigations using this model.
The limited cytokine analysis carried out in this model is interesting since the 
reductions found in the levels of IL-4 and IL-10 mRNA are consistent with the earlier 
finding that reduced circulating cytotoxic alloantibody is associated with prolonged 
graft survival. IL-4 provides help for antibody production by B cells (Paul and Ohara,
1987) and IL-10 is a costimulatory factor for B cell growth, differentiation and Ig 
secretion (Defrance et al, 1992). Some caution is required in equating detection of 
IL-4 and IL-10 mRNA with the presence or absence of Th2 CD4+ cells: non­
lymphoid cells may under certain conditions produce IL-10 (Broski and Halloran, 
1994) and IL-4 may be produced by mast cells and basophils (Plaut et al, 1989).
The ability of DSBT, used in conjunction with transient immunosuppression, 
to produce long-term tolerance to a subsequent allograft has considerable 
implications for clinical transplantation. DSBT alone has been abandoned almost 
completely in clinical practice due to both the theoretical risk seen in animal studies 
and the real risk, confirmed clinically, of sensitising the host to donor antigen. Such 
sensitisation leads to accelerated or hyperacute rejection of an allograft as a result of 
the recipient developing anti-donor HLA class I cytotoxic antibody. The use of
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cyclosporin A simultaneous with blood transfusion has been shown, by measurement 
of antibody level, to reduce the risk of allosensitisation in the rat (Cunningham et al.,
1988). In the present study, this combination was shown to confer long-term donor- 
specific protection to both a fully disparate graft and also to a pure class I MHC- 
disparate graft in which alloantibody is known to be essential for graft destruction.
The precise mechanism underlying this effect is not yet clear but would 
appear to be peripheral in nature. It is likely that an alteration in the ability of the 
CD4+ T helper cell to effectively orchestrate the immune response to the graft is 
central to this effect. This study does not support the belief that transplant tolerance is 
associated with polarisation of the cytokine network in favour of a Th2 response. 
Rather it would appear that the cytokine profile in tolerant grafts is variable and may 
well depend on such factors as the type of graft, the MHC disparity and in particular 
the strategy used for tolerance induction.
In clinical transplantation indirect presentation is believed to assume greater 
importance after the early post transplant period where direct allorecognition, driven 
by donor dendritic cells, is believed to predominate. This may suggest that the late 
graft loss, seen in clinical practice, from chronic rejection is due to indirect 
presentation by self-restricted alloreactive T cells (Bradley, 1996).
In rodent transplant models allograft rejection tends to be almost exclusively 
attributed to cellular effector mechanisms, notably cytotoxic T cells and DTH (Hall, 
1991). In this model the undoubted role of alloantibody mediated rejection gives it 
considerable clinical relevance given the relatively greater role of alloantibody in the
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human compared to the rat immune system (Bradley et al., 1992). Whether this 
protocol has any effect on presensitised recipients who already have high levels of 
circulating anti-class I antibody remains to be addressed and is clearly of interest in a 
clinical setting.
7.4 Summary
1 Tolerised grafts are heavily infiltrated with mononuclear cells but 
these lack IL-2R expression suggesting that they have been inactivated 
in some way.
2 Graft adaptation is minimal and this may reflect an increased role for 
indirect presentation in the high responder rat strain models.
3 This model of tolerance appears to be peripheral in nature.
4 Graft acceptance correlates with a reduction in all classes of cytotoxic 
alloantibody.
5 High levels of intragraft IL-4 and 10 seen in rejecting grafts are absent 
in tolerised grafts.
6 No evidence was found to support Th2 cells being tolerogenic.
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CHAPTER EIGHT 
Final Discussion
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Less than forty years have elapsed since early reports of successful renal 
transplantation between unrelated donors and recipients (Murray et al, 1963). 
Progress in transplantation has led to it becoming the treatment of choice for end- 
stage renal failure with few absolute contraindications. Most contraindications to 
transplant are relative and a consequence of a critical shortage of cadaveric organ 
donors. The number of renal transplants performed annually in the U.K. grew rapidly 
from 1974 (<450) to 1990 (>1800) but has since plateaued (Moore, 1997). Currently 
the U.K. transplant waiting list is rising by some 250 potential recipients a year as 
demand exceeds supply.
Clinical outcome following renal transplant appears initially to be highly 
satisfactory with 1-year patient and graft survival in excess of 95% and 90% 
respectively (UKTSSA, Bristol, 1994). By 5 years post transplant however, graft 
survival is in the region of only 50-60% and continues to fall thereafter (Belger et al., 
1997). Thus rejection remains the main cause of graft loss despite an increasingly 
sophisticated array of anti-rejection drugs. In addition to being unable to fully protect 
the allograft such drugs have very significant side effects. The long-term incidence of 
malignancies, primarily skin and lymphoid cancers, present the greatest concern 
(Penn, 1990; Barroso-Vicens et al., 1997). The ability to withdraw
immunosuppression after an initial induction period designed to facilitate tolerance, 
would diminish these side effects. Currently this is not possible due to the risk of 
rejection and graft loss. Research into potential strategies for inducing tolerance is
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vital if we are to be able to maximise the benefit of limited organ availability while 
avoiding immunosuppressive dangers.
Tolerance without the need for immunosuppressive drugs has been achieved 
in many animal models. One of the earliest of these models was donor-specific blood 
transfusion (DSBT)-pretreatment prior to renal transplantation in the DA into PVG 
rat strain combination (Fabre and Morris, 1972). This model was used in the early 
part of the current study. Despite the prolonged period since this model was first 
described the mechanism of tolerance induction remains elusive and worthy of 
further study. One criticism of the model is the relative ease of tolerance induction as 
the PVG rat is a low responder to DA alloantigens (Butcher and Howard, 1982). 
Consequently we sought to develop a model of DSBT induced tolerance that was 
effective in high responder strain combinations and so compare the two models. This 
was successfully achieved by the addition of a short course of cyclosporin A to the 
first of a series of DSBT’s.
The experiments reported herein, generated several interesting findings which 
contribute to an understanding of the blood transfusion effect. The powerful 
responses to alloantigens and hence the mechanisms of graft rejection are now 
accepted to revolve around the interaction of host T cells and the allo-MHC 
molecules contained within the graft (Murphy and Sayegh, 1996). Two methods for 
recognition of such foreign antigens exist and are described as “direct” and 
“indirect”(Lechler and Batchelor, 1982). “Direct” recognition involves the recipient 
T cell recognising intact allo-MHC on the surface of donor cells while the “indirect”
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pathway allows for recipient T cells to recognise processed allo-MHC presented by 
recipient antigen presenting cells. The relative importance of each of these pathways 
is under considerable debate but the “indirect” pathway may well prove to be of 
particular importance in terms of the chronic graft loss, despite immunosuppression, 
that is a major problem in clinical transplantation (Liu et al., 1993). In contrast the 
“direct” pathway may be responsible for early acute rejection (Braun et al., 1993) 
since the graft initially contains a significant number of donor-derived passenger 
APC’s (such as dendritic cells) that are capable of providing the necessary 
costimulatory signals for full T cell activation (Larsen et al, 1992).
In our study the low responder PVG rat would appear to be poor at mounting 
responses via the “indirect” pathway and therefore the rapid rejection of DA kidneys 
by unmodified PVG recipients is primarily achieved via the “direct” pathway. The 
prolonged survival of “parked” DA grafts when retransplanted into a second 
unmodified PVG rat and the inability of sensitised lymph node cells to damage 
longstanding grafts both point to such a deficit in “indirect” presentation. This 
apparent loss of immunogenicity of the transplanted organ has been referred to as 
graft adaptation by other workers (Marquet et al., 1985). The long-term survival of 
the kidney allograft seen with a short course of cyclosporin A may be explained if the 
cyclosporin A prevents early “direct” initiation of rejection while passenger cells 
leave the kidney. Subsequently it no longer presents a target for “direct” rejection and 
in the absence of an active “indirect” pathway long-term survival occurs. The 
transient rise we often noted in serum urea and creatinine in DSBT-pretreated rats
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could suggest that protection by DSBT alone is relatively limited but is sufficient to 
allow long-term graft survival because the rejection mechanisms in this strain 
combination are only operative until the passenger leukocytes have left the graft.
Despite the results cited above graft adaptation is not the only reason for the 
prolonged survival seen in the DA into PVG renal allograft model. We have shown 
that second grafts (kidney and heart) are also accepted and that proliferation in the 
MLR is decreased. Thus DSBT does lead to tolerance and the mechanism behind this 
effect is peripheral in nature as thymectomy does not alter these findings. Several 
mechanisms have been proposed to explain the tolerant state induced by DSBT 
although no consensus has yet been reached as to their relative importance.
In 1978 Lafferty proposed the “two-signal hypothesis”. This stated that if the 
T cell encounters antigen in the absence of a second costimulatory signal from the 
antigen presenting cell then the T cell becomes functionally paralysed or “anergic”. 
The later descriptions of the roles of the CD28 and B7/BB1 molecules in supplying 
such signals (Schwartz, 1995) gave the two signal hypothesis considerable impetus. 
Exogenous IL-2 has been shown to “rescue” cells from such an anergic state (Heath 
et al., 1992) and further to be able to abrogate DSBT-induced graft tolerance 
(Dallman et al., 1991). If DSBT is serving to block such second signals then this is 
an attractive concept by which to explain DSBT-induced tolerance. One criticism of 
anergy as a major source of tolerance is that if the host has to subsequently initiate 
immune responses against separate pathogens in tissues then these potentially 
reactive cells may be rescued by signals or cytokines from “bystander” cells
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(Bretscher, 1992). If as implied above, the PVG rat can only mount a response by 
“direct” presentation while passenger leukocytes are still present in the graft then this 
potential late loss of tolerance is of little importance in this model. Exogenously 
administered IL-2 has been reported to abrogate DSBT-induced tolerance when 
administered at the time of transplant (Dallman et al, 1991). We would hypothesis 
that in this model delayed administration of IL-2 would fail to bring about rejection 
of stable grafts, an area for future investigation. The rejection of grafts in high 
responder strain combinations treated with either a short course of cyclosporin or 
with DSBT-pretreatment alone, would imply that “indirect” presentation is also 
important in such cases and that any tolerogenic mechanism would require a long­
term mode of action.
Donor-specific microchimerism (DSM), whereby low levels of donor 
leukocytes may persist and multiply in the periphery of the recipient, has been 
suggested as a possible mechanism for induction and maintenance of tolerance 
(Murase et al., 1996). DSBT and bone marrow transfusions prior to transplant have 
been demonstrated to lead to DSM (McDaniel et al, 1994; Sakrada et al, 1997). 
What is not clear is whether chimerism is an essential requirement for tolerance as 
Starzl has implied previously (Starzl et al, 1993) or is simply an epiphenomenon of 
successful organ transplantation (Schlitt, 1997). More recent studies have tended to 
support the concept that DSM is associated with but is not essential for tolerance 
(Sivasai et al, 1997; Sakurada et al, 1997). The close connection between tolerance 
induction and microchimerism has led to several attempts to augment leukocyte
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numbers at the time of transplant in the hope of achieving a tolerant state (Barber et 
al, 1991; Tsaroucha et al., 1997). The model of tolerance in high responder rat strain 
combinations that we developed using repeated DSBT given with cyclosporin A 
could be explained by microchimerism induction although we did not look 
specifically for this in our studies. Microchimerism can be viewed merely as a form 
of antigen persistence as is the continuing presence of the graft itself. The idea that 
persistent antigenic stimulation may be tolerogenic has been proposed by some 
investigators (Hamano et al., 1996). Chen and coworkers (1993) demonstrated that 
the tolerant state could be lost following graft removal. They proposed chronic 
desensitisation of the T cell receptor by persistent alloantigen as a possible 
mechanism of tolerance since they were unable to demonstrate either a suppressive 
serum factor or any regulatory cell production. Several other groups however have 
been able to adoptively transfer tolerance in different models (Hall et al., 1990; Qin 
et al, 1993; Scully et al, 1994). In addition Field and coworkers (1997) describe 
“immunoregulatory” CD4 cells with the capacity to maintain tolerance potentially via 
a variety of mechanisms depending on the given situation being studied.
The role of cytokines in the pathophysiology of acute and chronic allograft 
rejection is now widely debated (reviewed by Nadeau et al, 1996) and a considerable 
amount of our study involved the examination of cytokine profiles seen in rejecting 
and tolerised grafts in both low and high responder models of transplant tolerance. 
The Thl/Th2 paradigm, with the Th2 phenotype being associated with tolerance and 
a Thl phenotype closely linked with rejection has been reported by several groups
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(Lowry, 1993; Chen and Field, 1996). Our studies of the kinetics of IL-2 production 
in rejecting allografts and the abolition of the IL-2 peak on day 4 post transplant by 
DSBT pretreatment are comparable with other reports (Dallman et al., 1991; Bugeon 
et al., 1993) and agree that prevention of Thl responses is critical for tolerance 
induction. In contrast our finding of high Th2 cytokine levels in rejecting R8 grafts 
and their abolition by DSBT/cyclosporin A-pretreatment clearly falls outwith the 
current Thl/Th2 paradigm. The abolition of the alloantibody responses of all IgG 
isotypes, demonstrated following DSBT/cyclosporin A-pretreatment, correlates with 
the cytokine mRNA findings and also with the previously published finding that 
cytotoxic alloantibody is a major cause of graft rejection in this strain combination 
(Morton et al, 1993). At least one other study of DSBT-pretreated recipients has also 
reported a decrease in both Th2 and Thl cytokines (Josien et al., 1995). In addition 
several studies have shown high IL-4 and IL-10 mRNA levels in rejecting grafts 
(Dallman et al, 1991; Chan et al., 1995). While there are several studies that support 
the Thl/Th2 paradigm (Siegling et al., 1994; Hamano et al., 1997) it would appear 
that the intragraft cytokine profile in tolerant grafts is variable and likely to depend 
on such factors as the type of graft, the MHC disparity and in particular the strategy 
used for tolerance production.
It is clear that tolerance production can be achieved in the human situation. 
There are now several reports of long-term allograft survival after discontinuation of 
all immunosuppressive therapies following successful liver transplantation and also 
similar isolated reports of renal allograft survival (Starzl et al., 1993). A study in
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rhesus monkeys of pretransplant blood transfusions and cyclosporin A has shown 
long-term survival of renal allografts following withdrawal of all immunosuppression 
but only if the transfusion was donor-specific (Leonard et al, 1996). The problem 
with either reducing or withdrawing immunosuppression is that with our current level 
of understanding of tolerance we are unable to predict which patients this might be 
appropriate for and such attempts have a substantial risk of leading to graft loss. 
Currently patient noncompliance with immunosuppressive regimes has been reported 
to be one of the major causes of kidney graft failure (Garcia et al, 1997).
The potential for “indirect” pathways of rejection to play a major role in 
chronic rejection has been noted by several investigators (Bradley et al, 1992; Braun 
et al, 1993). This form of graft rejection primarily affects the arteries in the graft 
leading to vascular occlusion and graft loss. In clinical terms it has been suggested 
that periodic assessment of the indirect allorecognition pathways in renal transplant 
recipients, with long-term well-functioning grafts, may allow closer monitoring of 
the level of immunosuppression required to optimise long-term graft function and 
reduction of such levels where appropriate (Iniotaki-Theodoraki et al., 1997). More 
interestingly, in animal models DSBT has been shown to prevent the onset of chronic 
(vascular) rejection (Wood et al, 1996). The use of multiple blood transfusions has 
also been shown to have a profound effect on indirect T cell allorecognition even 
without the use of concomitant immunosuppression (Sawyer and Fabre, 1997). 
Chronic rejection is now believed to be the cause of graft loss more often than acute 
rejection (Orosz et al, 1997). If peri/pre-transplant blood transfusions can be shown
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to reduce chronic rejection then their use may become more widespread once again. 
Currently only a small number of transplant centres worldwide still include donor- 
specific blood or bone marrow transfusion in their protocols for living related renal 
transplants (Okazaki et al, 1997) or living related liver allografting (Ricordi et al, 
1997). Both of these groups claim enhanced graft survival with their protocols and in 
liver transplantation increasing the number of transfusions appears to increase the 
beneficial effect. Similarly a small number of groups have given donor-strain blood 
or bone marrow at the time of cadaveric allografting and long-term results from these 
groups may reveal potential advantages to this strategy (Alexander et al, 1992).
Clearly we would hope that as our understanding of both the mechanisms for 
rejection and also for tolerance induction continue to grow many of the tantalising 
prospects for organ transplantation shown in animal models will facilitate their use in 
the field of clinical transplantation.
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